https://www.pharmaceutical-technology.com/data-insights/tisotumab-vedotin-genmab-metastatic-colorectal-cancer-likelihood-of-approval/ 2024-09-09T05:06:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tisotumab-vedotin-genmab-solid-tumor-likelihood-of-approval/ 2024-09-09T05:06:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tisotumab-vedotin-genmab-endometrial-cancer-likelihood-of-approval/ 2024-09-09T05:06:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tisotumab-vedotin-genmab-ovarian-cancer-likelihood-of-approval/ 2024-09-09T05:06:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tisotumab-vedotin-genmab-pancreatic-cancer-likelihood-of-approval/ 2024-09-09T05:06:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tisotumab-vedotin-genmab-bladder-cancer-likelihood-of-approval/ 2024-09-09T05:06:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nx-5948-nurix-therapeutics-relapsed-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2025-01-21T01:35:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nx-5948-nurix-therapeutics-refractory-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2025-01-21T01:35:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dalbavancin-abbvie-methicillin-resistant-staphylococcus-aureus-mrsa-infections-likelihood-of-approval/ 2025-01-21T01:35:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/volrustomig-astrazeneca-oropharyngeal-cancer-likelihood-of-approval/ 2025-01-21T01:34:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/volrustomig-astrazeneca-oral-cavity-mouth-cancer-likelihood-of-approval/ 2025-01-21T01:35:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/volrustomig-astrazeneca-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2025-01-21T01:35:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/volrustomig-astrazeneca-hypopharyngeal-cancer-likelihood-of-approval/ 2025-01-21T01:34:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/volrustomig-astrazeneca-laryngeal-cancer-likelihood-of-approval/ 2025-01-21T01:34:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lenvatinib-mesylate-eisai-transitional-cell-cancer-urothelial-cell-cancer-likelihood-of-approval/ 2025-01-21T01:34:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lenvatinib-mesylate-eisai-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2025-01-21T01:34:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lenvatinib-mesylate-eisai-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2025-01-21T01:34:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/regenxbio-advances-two-candidates-to-make-waves-in-the-cns-space/ 2024-02-08T17:14:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-and-ema-team-up-to-expedite-complex-generic-drug-development/ 2024-02-08T16:23:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/nicox-partners-with-kowa-to-develop-eye-therapy-in-japan/ 2024-02-08T15:47:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/novo-nordisk-to-acquire-cmo-giant-catalent-for-16-5bn/ 2024-03-27T12:13:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/medicines-access-unlocking-the-immense-potential-in-cell-and-gene-therapy/ 2024-02-09T11:02:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/otsukas-abilify-maintena-dual-drug-expiry-signals-sales-decline/ 2024-02-08T15:00:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/international-gaucher-alliance-marks-30th-year-unveils-five-year-strategic-plan-to-2029/ 2024-02-08T14:36:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/bridgebio-kyowa-kirin-skeletal-dysplasia/ 2024-02-08T11:21:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/telix-acquire-qsam-biosciences/ 2024-02-08T11:23:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-bristol-myers-squibb-nsclc/ 2024-02-08T09:04:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/jazz-redx-kras-inhibitor/ 2024-02-08T07:52:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vobramitamab-duocarmazine-macrogenics-net-present-value/ 2024-07-02T02:02:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ligelizumab-novartis-food-allergy-likelihood-of-approval/ 2024-02-08T03:58:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/irinotecan-hydrochloride-ipsen-neuroendocrine-carcinoma-likelihood-of-approval/ 2024-09-09T04:20:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sacubitril-valsartan-novartis-hypertrophic-cardiomyopathy-likelihood-of-approval/ 2024-07-05T06:22:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sj-01-shanghai-bao-pharmaceuticals-anemia-likelihood-of-approval-2/ 2024-12-25T18:25:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trastuzumab-biosimilar-qilu-pharmaceutical-human-epidermal-growth-factor-receptor-2-positive-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2024-02-08T03:56:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/prgn-3006-precigen-chronic-myelomonocytic-leukemia-cmml-likelihood-of-approval/ 2024-06-14T04:07:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/prgn-3006-precigen-myelodysplastic-syndrome-likelihood-of-approval/ 2024-06-14T04:07:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trastuzumab-biosimilar-sino-biopharmaceutical-metastatic-breast-cancer-likelihood-of-approval/ 2024-02-08T03:50:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/apatinib-mesylate-elevar-therapeutics-gastroesophageal-ge-junction-carcinomas-likelihood-of-approval-2/ 2024-12-25T18:03:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trastuzumab-biosimilar-accord-healthcare-adenocarcinoma-of-the-gastroesophageal-junction-likelihood-of-approval/ 2024-02-08T03:43:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trastuzumab-biosimilar-accord-healthcare-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2024-02-08T03:43:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trastuzumab-biosimilar-accord-healthcare-gastric-cancer-likelihood-of-approval/ 2024-02-08T03:43:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trastuzumab-biosimilar-accord-healthcare-metastatic-breast-cancer-likelihood-of-approval/ 2024-02-08T03:43:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xen-1101-xenon-pharmaceuticals-major-depressive-disorder-likelihood-of-approval/ 2024-03-18T23:19:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adipose-tissue-derived-mesenchymal-stromal-stem-cells-cell2cure-diabetic-foot-ulcers-likelihood-of-approval-2/ 2024-12-25T17:52:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fpi-2265-fusion-pharmaceuticals-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval-2/ 2024-12-25T17:39:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/docetaxel-zhuhai-beihai-biotech-solid-tumor-likelihood-of-approval/ 2024-07-05T05:45:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/empasiprubart-argenx-dermatomyositis-likelihood-of-approval-2/ 2024-12-25T17:26:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/everolimus-novartis-myelodysplastic-syndrome-likelihood-of-approval-2/ 2024-12-25T17:20:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pasireotide-recordati-hypoglycemia-likelihood-of-approval/ 2025-01-19T17:19:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pasireotide-recordati-medullary-thyroid-cancer-likelihood-of-approval/ 2024-02-08T02:49:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trastuzumab-duocarmazine-byondis-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval-2/ 2024-12-25T17:15:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vepdegestrant-arvinas-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval-2/ 2024-12-25T17:12:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lysergic-acid-diethylamide-mind-medicine-mindmed-generalized-anxiety-disorder-gad-likelihood-of-approval-2/ 2024-12-25T17:12:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/stp-938-step-pharma-marginal-zone-b-cell-lymphoma-likelihood-of-approval-2/ 2024-12-25T17:10:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lysergic-acid-diethylamide-mind-medicine-mindmed-major-depressive-disorder-likelihood-of-approval-2/ 2024-12-25T17:09:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/minocycline-hydrochloride-er-promius-pharma-rosacea-likelihood-of-approval-2/ 2024-12-25T17:08:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sisunatovir-hydrochloride-pfizer-respiratory-syncytial-virus-rsv-infections-likelihood-of-approval-2/ 2024-12-25T17:04:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/everolimus-novartis-acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-likelihood-of-approval-3/ 2024-02-08T02:12:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/uncategorized/everolimus-novartis-acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-likelihood-of-approval-2/ 2024-02-08T02:06:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-clear-verus-ind-for-glp-1-ra-associated-muscle-loss-drug/ 2024-02-07T20:00:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/stalicla-secures-funds-for-late-stage-assets-amid-cns-buzz/ 2024-02-12T10:47:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/immunome-wins-ayalas-phase-iii-desmoid-tumour-candidate-for-50m/ 2024-02-07T12:03:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/gilead-net-income-fy23/ 2024-02-07T11:19:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/five-ways-disconnected-consent-is-impacting-patient-experiences/ 2024-02-07T11:04:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/eli-lilly-q4-2023-income/ 2024-02-07T11:19:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-review-gsk-rsv-vaccine/ 2024-02-07T09:05:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/astrazeneca-300m-facility-maryland/ 2024-02-07T09:30:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/rani-reports-positive-data-for-non-injectable-stelara-biosimilar/ 2024-02-06T16:57:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/novartis-eyes-2-9bn-morphosys-buyout-to-expand-oncology-pipeline/ 2024-02-06T16:42:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/alternative-therapies-impending-threat-of-amr/ 2024-02-06T14:31:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/mithra-sets-out-plan-to-rescue-cash-runway/ 2024-02-15T10:26:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/china-nmpa-fermion-tyk2-jh2-inhibitor/ 2024-02-06T10:50:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/jj-touts-success-of-nipocalimab-in-two-rare-disease-trials/ 2024-02-06T10:38:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/health-canada-chiesi-myalepta/ 2024-02-06T10:28:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/silence-therapeutics-private-placement/ 2024-02-06T14:42:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/incyte-morphosys-tafasitamab/ 2024-02-06T09:29:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tividenofusp-alfa-denali-therapeutics-net-present-value/ 2024-06-13T18:55:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lepodisiran-sodium-eli-lilly-and-co-net-present-value/ 2024-05-16T02:00:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/granite-001-gritstone-bio-net-present-value/ 2024-06-13T18:50:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tozorakimab-astrazeneca-net-present-value/ 2024-12-13T02:50:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/apraglutide-ironwood-pharmaceuticals-net-present-value/ 2024-06-13T18:47:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mino-lok-citius-pharmaceuticals-net-present-value/ 2024-07-02T02:02:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tlx-101-telix-pharmaceuticals-net-present-value/ 2024-05-16T02:09:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nanatinostat-valganciclovir-viracta-therapeutics-net-present-value/ 2024-06-13T18:55:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/novo-holdings-acquires-catalent-for-16-5bn/ 2024-02-08T12:28:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/valneva-sells-ixchiq-priority-voucher-for-103m-to-fuel-rd/ 2024-02-05T14:35:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/contentious-medicare-price-negotiations-underway-as-us-drug-prices-rise/ 2024-02-09T20:18:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/anamar-secures-double-orphan-drug-designation-for-systemic-sclerosis-drug/ 2024-02-05T13:25:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/abbvie-full-year-2023-revenue/ 2024-02-05T11:14:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/regeneron-linvoseltamab-application-review/ 2024-02-05T11:10:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ema-application-genmab-pfizer/ 2024-02-05T08:14:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/inmagene-licence-hutchmed-drugs/ 2024-02-05T08:06:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/bms-reports-2-revenue-loss-in-2023-after-revlimid-generics-hurt-sales/ 2024-02-02T17:25:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/igc-pharma-heads-towards-a-phase-i-study-for-alzheimers-disease/ 2024-02-02T17:12:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/abbvie-wins-uk-nice-endorsement-for-subcutaneous-tepkinly-in-dlbcl/ 2024-02-02T15:08:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/as-englands-virus-hospitalisations-surge-flu-vaccines-evolve/ 2024-02-14T23:17:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/scottish-company-secures-4-2m-to-develop-3d-printed-micro-tumours/ 2025-06-27T14:51:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/limmatech-funding-vaccine-development/ 2024-02-02T10:42:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/biosyngen-liver-cancer-therapy/ 2024-02-02T10:32:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/sanofi-graviton-strategic-investment/ 2024-02-02T09:18:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/tyra-fda-rare-paediatric-disease-status/ 2024-02-02T09:17:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/keytruda-remains-merck-cos-biggest-2023-success-story-as-patent-expiry-looms/ 2024-02-01T18:10:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/the-new-technologies-helping-biopharmaceutical-trailblazers-accelerate-progress-from-research-to-market-2/ 2025-05-02T10:17:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/healthcare-providers-favour-pricing-control-as-us-drug-costs-soar/ 2024-02-01T15:32:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/vivet-wins-5-3m-grant-to-develop-gene-therapy-for-rare-metabolic-disorder/ 2024-02-01T14:51:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/excellence-awards/awards/2023-excellence-awards-and-rankings-report/ 2024-02-02T05:07:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/neophore-adds-12-2m-in-series-b-extension-for-immuno-oncology-pipeline/ 2024-02-01T14:01:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/novartis-fy2023-net-income/ 2024-02-01T11:07:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/almirall-microsoft-dermatological-drug/ 2024-02-01T11:04:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/takeda-protagonist-rusfertide-deal/ 2024-02-01T08:30:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/uk-mhra-gsk-momelotinib/ 2024-02-01T08:22:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/cms-sets-up-negotiating-framework-for-expensive-sickle-cell-disease-gene-therapies/ 2024-02-07T10:06:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/revolo-advances-plans-to-tackle-eosinophilic-esophagitis-with-orphan-drug-tag/ 2024-01-31T17:20:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/out-with-the-old-in-with-the-new-decoding-biosimilar-access-with-vpag/ 2024-01-31T16:55:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/defenders-plans-for-motion-sickness-nasal-gel-stop-with-fda-rejection/ 2024-01-31T16:34:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/biogen-bids-farewell-to-aduhelm-after-tumultuous-journey-in-alzheimers/ 2024-01-31T16:25:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/phase-iii-study-halted-ferrer-oral-edaravone-disappoints-in-als/ 2024-01-31T15:44:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/germanys-ministry-of-health-accusations-of-worsening-market-conditions/ 2024-01-31T15:33:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/fda-review-designations-crispr-drugs-in-2023/ 2024-01-31T15:08:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/can-musks-bci-company-neuralink-be-trusted-to-put-chips-in-your-brain/ 2024-01-31T14:48:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/astellas-padcev-keytruda-japan/ 2024-01-31T11:13:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/pfizer-revenue-2023/ 2024-01-31T11:13:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/interviews/qa-regulatory-reform-necessary-to-improve-obesity-drug-access/ 2024-02-13T19:18:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/axplora-investment-french/ 2024-01-31T10:05:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/regeneron-cell-medicines/ 2024-02-07T10:03:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/vertex-aims-for-approval-after-phase-iii-win-with-non-opioid-pain-reliever/ 2024-04-19T15:50:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/setting-up-trials-in-apac-and-middle-east-can-boost-patient-recruitment/ 2024-01-30T16:18:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/sanofi-partners-with-synthekine-to-develop-il-10-therapeutics/ 2024-01-30T16:04:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/aqemia-wins-32-5m-for-generative-ai-powered-drug-discovery-platform/ 2024-01-30T15:33:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/transient-expression-car-t-cell-therapies-lipid-nanoparticles/ 2024-01-30T14:52:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/gsk-rsv-vaccine-adults/ 2024-01-30T11:15:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/mhra-approves-napps-rezzayo/ 2024-01-30T11:12:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/gilead-arcus-oncology-partnership/ 2024-01-30T09:26:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-takeda-cidp/ 2024-01-30T09:23:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/navigating-clinical-trial-operations-in-the-era-of-collaboration/ 2024-01-29T21:56:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/king-charles-diagnosis-raises-awareness-on-prostate-condition/ 2024-01-29T17:56:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ascidian-launches-first-ever-clinical-study-of-rna-exon-editor-for-vision-loss/ 2024-01-29T18:48:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/moderna-leads-the-development-of-mrna-vaccines-in-infectious-diseases/ 2024-01-29T15:07:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/pfizer-and-astellas-seek-updated-ema-approval-for-padcev-with-keytruda/ 2024-01-29T15:02:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/merck-is-on-the-lookout-for-more-opportunities-within-immunology/ 2024-01-29T13:59:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/cell-and-gene-therapies-top-pharmaceutical-industry-trend-2024/ 2024-01-30T09:43:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/cristalia-licensing-deal-formosa/ 2024-01-29T10:45:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-daiichi-sankyo-astrazeneca-enhertu/ 2024-01-29T10:49:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/celltrion-seeks-fda-approval-biosimilar/ 2024-01-29T09:47:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/bms-abecma-recommended-for-approval/ 2024-01-29T09:50:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/drug-shortages-challenge-type-2-diabetes-patients-in-the-uk/ 2024-01-26T20:28:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/car-t-therapies-and-cancer-risk-no-easy-answers-for-the-fda/ 2024-01-26T17:59:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/atossa-therapeutics-progresses-phase-ii-preventative-breast-cancer-therapy/ 2024-02-01T17:19:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-expands-approval-of-dupixent-for-eosinophilic-esophagitis-in-children/ 2024-01-26T13:54:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/travere-signs-120m-licensing-deal-with-renalys-for-sparsentan-in-asia/ 2024-01-26T11:37:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/lava-signs-collaboration-agreement-with-msd-for-prostate-cancer-therapy/ 2024-01-25T17:43:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/repare-bags-40m-from-roche-as-solid-tumour-trial-begins/ 2024-01-25T16:32:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/gileads-tecartus-escapes-harsher-classwide-boxed-warning-for-car-t-therapies/ 2024-01-25T16:18:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/what-is-the-uks-covid-19-drug-armoury-like-amid-rising-infection-levels/ 2024-01-25T22:42:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/harnessing-the-untapped-potential-of-medicines-access/ 2024-02-06T11:29:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/evaxion-develop-vaccines-cancer/ 2024-01-25T10:46:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/kyowa-kirin-acquires-orchard/ 2024-01-31T09:38:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/synnovation-102m-funding-therapy-pipeline/ 2024-01-25T08:42:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-denies-approval-theratechnologies-tesamorelin/ 2024-01-25T08:36:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aur-105-aurigene-oncology-leukemia-likelihood-of-approval/ 2024-03-18T23:41:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/padeliporfin-potassium-impact-biotech-esophageal-cancer-likelihood-of-approval/ 2024-07-05T06:14:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aldesleukin-iovance-biotherapeutics-graft-versus-host-disease-gvhd-likelihood-of-approval/ 2024-06-14T02:01:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/hhs-reiterates-plans-to-allow-paxlovid-access-regardless-of-insurance/ 2024-01-24T16:30:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/hhs-announces-2024-actions-to-protect-contraceptive-care/ 2024-01-24T15:59:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/4dmt-secures-rare-paediatric-designation-for-cystic-fibrosis-gene-therapy/ 2024-01-31T09:37:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/naya-buys-gene-therapy-company-florida-biotech-for-20m/ 2024-01-31T09:38:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/eracal-novo-nordisk-obesity-treatment/ 2024-01-24T10:37:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/bristol-myers-squibb-mirati-acquisition/ 2024-01-24T10:33:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/accent-secures-funding-cancer/ 2024-01-24T08:57:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/johnson-johnson-q4-2023-earnings/ 2024-01-24T08:34:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/cara-therapeutics-cuts-50-of-staff-and-drops-kidney-disease-program/ 2024-01-23T17:37:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/newly-launched-calluna-raises-81m-to-advance-monoclonal-antibody-pipeline/ 2024-01-23T17:03:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/genentech-signs-nanoparticle-deal-worth-up-to-644m-with-genedit/ 2024-01-24T10:15:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/sanofi-to-acquire-inhibrx/ 2024-01-23T10:48:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/inhalation-sciences-actarmo-deal/ 2024-01-23T10:49:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/mhra-strengthens-regulations-fluoroquinolone/ 2024-01-23T08:08:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ns-pharma-egpa-treatment/ 2024-01-23T07:58:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/a-sense-of-urgency-swirls-in-the-uk-pharma-regulatory-landscape/ 2024-01-19T22:20:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/f-hoffmann-la-roche-in-cybersecurity-theme-innovation-strategy/ 2024-01-23T12:19:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/amgen-in-artificial-intelligence-theme-innovation-strategy/ 2024-08-01T06:11:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bayer-in-artificial-intelligence-theme-innovation-strategy/ 2024-08-01T06:12:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/memorial-sloan-kettering-cancer-center-in-artificial-intelligence-theme-innovation-strategy/ 2024-03-11T11:43:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jnj-87890387-johnson-johnson-solid-tumor-likelihood-of-approval/ 2025-01-21T01:34:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mac-001-macera-therapeutics-gastric-cancer-likelihood-of-approval/ 2024-07-05T17:59:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/repurposed-drugs-luminous-mind-depression-likelihood-of-approval/ 2025-01-21T01:34:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/repurposed-drugs-luminous-mind-anxiety-disorders-likelihood-of-approval/ 2025-01-21T01:34:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vx-828-vertex-pharmaceuticals-cystic-fibrosis-likelihood-of-approval/ 2024-01-23T02:11:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jnj-88549968-johnson-johnson-myelofibrosis-likelihood-of-approval/ 2024-01-23T02:10:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jnj-88549968-johnson-johnson-essential-thrombocythemia-likelihood-of-approval/ 2024-01-23T02:10:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jnj-87801493-johnson-johnson-b-cell-non-hodgkin-lymphoma-likelihood-of-approval/ 2024-09-09T05:05:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mc-150-chongqing-precision-biotech-primary-mediastinal-b-cell-lymphoma-likelihood-of-approval/ 2025-01-21T01:34:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bnt-314-biontech-solid-tumor-likelihood-of-approval/ 2025-01-21T01:34:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/r-01-hangzhou-neoantigen-therapeutics-metastatic-bile-duct-cancer-likelihood-of-approval/ 2024-07-05T17:59:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/r-01-hangzhou-neoantigen-therapeutics-metastatic-colorectal-cancer-likelihood-of-approval/ 2024-07-05T17:59:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/r-01-hangzhou-neoantigen-therapeutics-gastrointestinal-tract-cancer-likelihood-of-approval/ 2024-07-05T17:59:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/r-01-hangzhou-neoantigen-therapeutics-metastatic-pancreatic-cancer-likelihood-of-approval/ 2024-07-05T17:59:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/r-01-hangzhou-neoantigen-therapeutics-metastatic-hepatocellular-carcinoma-hcc-likelihood-of-approval/ 2024-07-05T17:59:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/torl-4500-torl-biotherapeutics-solid-tumor-likelihood-of-approval/ 2025-01-21T01:34:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cgc-729-cure-genetics-metastatic-renal-cell-carcinoma-likelihood-of-approval/ 2025-01-21T01:34:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rd-1302-nanjing-bioheng-biotech-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-21T01:34:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rd-1302-nanjing-bioheng-biotech-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-21T01:33:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lpxti-641-lapix-therapeutics-neuromyelitis-optica-devic-s-syndrome-likelihood-of-approval/ 2025-01-21T01:33:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lpxti-641-lapix-therapeutics-demyelinating-diseases-likelihood-of-approval/ 2025-01-21T01:33:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fkpc-101-cellvax-therapeutics-metastatic-prostate-cancer-likelihood-of-approval/ 2025-01-21T01:33:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/df-9001-dragonfly-therapeutics-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2024-07-05T17:58:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/df-9001-dragonfly-therapeutics-metastatic-renal-cell-carcinoma-likelihood-of-approval/ 2024-07-05T17:58:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/df-9001-dragonfly-therapeutics-oral-cavity-mouth-cancer-likelihood-of-approval/ 2024-07-05T17:58:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/df-9001-dragonfly-therapeutics-oropharyngeal-cancer-likelihood-of-approval/ 2024-07-05T17:58:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/df-9001-dragonfly-therapeutics-laryngeal-cancer-likelihood-of-approval/ 2024-07-05T17:58:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/df-9001-dragonfly-therapeutics-hypopharyngeal-cancer-likelihood-of-approval/ 2024-07-05T17:58:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/df-9001-dragonfly-therapeutics-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-07-05T17:58:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vvn-461-viva-vision-biotech-ocular-inflammation-likelihood-of-approval/ 2025-01-21T01:33:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ql-335-qlsf-biotherapeutics-colorectal-cancer-likelihood-of-approval/ 2024-04-20T01:33:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hcp-2102-hanmi-pharmaceuticals-idiopathic-essential-hypertension-likelihood-of-approval/ 2024-01-23T01:28:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cbt102-a-commbio-therapeutics-phenylketonuria-pku-likelihood-of-approval/ 2024-01-23T01:28:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ndc-002-dr-noah-biotech-dementia-likelihood-of-approval/ 2025-01-21T01:33:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/scg-101-scg-cell-therapy-hepatocellular-carcinoma-likelihood-of-approval/ 2025-01-21T01:33:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zma-001-zymedi-pulmonary-arterial-hypertension-likelihood-of-approval/ 2024-09-09T05:05:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/iae-0972-sunho-china-biopharmaceutical-recurrent-head-and-neck-squamous-cell-carcinoma-likelihood-of-approval/ 2025-01-21T01:33:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/iae-0972-sunho-china-biopharmaceutical-metastatic-colorectal-cancer-likelihood-of-approval/ 2025-01-21T01:33:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/veroxen-microgen-tick-borne-encephalitis-likelihood-of-approval/ 2024-01-23T01:26:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/av-5124-viriom-influenzavirus-b-infections-likelihood-of-approval/ 2025-01-21T01:33:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pgn-edodm1-pepgen-myotonic-dystrophy-likelihood-of-approval/ 2025-01-21T01:33:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pembrolizumab-quavonlimab-merck-renal-cell-carcinoma-likelihood-of-approval/ 2025-01-21T01:33:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ank-101-ankyra-therapeutics-solid-tumor-likelihood-of-approval/ 2025-01-21T01:33:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/axitinib-sr-alcon-wet-neovascular-exudative-macular-degeneration-likelihood-of-approval/ 2024-09-09T05:05:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bs-006-wuhan-binhui-biopharmaceutical-cutaneous-squamous-cell-carcinoma-cscc-likelihood-of-approval/ 2024-09-09T05:05:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bs-006-wuhan-binhui-biopharmaceutical-solid-tumor-likelihood-of-approval/ 2024-09-09T05:05:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bs-006-wuhan-binhui-biopharmaceutical-metastatic-melanoma-likelihood-of-approval/ 2024-09-09T05:05:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bs-006-wuhan-binhui-biopharmaceutical-breast-cancer-likelihood-of-approval/ 2024-09-09T05:05:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/shr-1707-jiangsu-hengrui-medicine-alzheimer-s-disease-likelihood-of-approval/ 2025-01-21T01:33:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cytarabine-daunorubicin-cspc-pharmaceutical-group-acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-likelihood-of-approval/ 2024-01-23T01:17:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dalnicastobart-lyvgen-biopharma-advanced-malignancy-likelihood-of-approval/ 2025-01-21T01:32:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tivozanib-kyowa-kirin-wet-neovascular-exudative-macular-degeneration-likelihood-of-approval/ 2024-07-05T17:58:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tivozanib-kyowa-kirin-diabetic-macular-edema-likelihood-of-approval/ 2024-07-05T17:58:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sls-009-sellas-life-sciences-group-extranodal-marginal-zone-b-cell-lymphoma-mucosa-associated-lymphoid-tissue-or-malt-lymphoma-likelihood-of-approval/ 2025-01-21T01:32:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sls-009-sellas-life-sciences-group-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-21T01:32:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sls-009-sellas-life-sciences-group-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-21T01:32:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sls-009-sellas-life-sciences-group-peripheral-t-cell-lymphomas-ptcl-likelihood-of-approval/ 2025-01-21T01:32:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rd-07-nanjing-bioheng-biotech-adenocarcinoma-of-the-gastroesophageal-junction-likelihood-of-approval/ 2024-01-23T01:12:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rd-07-nanjing-bioheng-biotech-pancreatic-cancer-likelihood-of-approval/ 2024-01-23T01:12:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ql-415-qlsf-biotherapeutics-hematological-tumor-likelihood-of-approval/ 2025-01-21T01:32:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anx-1502-annexon-autoimmune-disorders-likelihood-of-approval/ 2025-01-21T01:32:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sh-105-shorla-oncology-ovarian-cancer-likelihood-of-approval/ 2024-02-08T19:27:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atg-101-antengene-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2025-01-21T01:32:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atg-101-antengene-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2025-01-21T01:32:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atg-101-antengene-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2025-01-21T01:32:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atg-101-antengene-gastric-cancer-likelihood-of-approval/ 2025-01-21T01:32:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atg-101-antengene-cervical-cancer-likelihood-of-approval/ 2025-01-21T01:32:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cna-3103-carina-biotech-metastatic-colorectal-cancer-likelihood-of-approval/ 2024-05-20T04:51:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tsha-102-astellas-pharma-rett-syndrome-likelihood-of-approval/ 2025-01-21T01:32:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rhenium-186re-obisbemeda-plus-therapeutics-lung-adenocarcinoma-likelihood-of-approval/ 2024-07-05T17:57:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rhenium-186re-obisbemeda-plus-therapeutics-kaposi-sarcoma-likelihood-of-approval/ 2024-07-05T17:57:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rhenium-186re-obisbemeda-plus-therapeutics-squamous-cell-carcinoma-likelihood-of-approval/ 2024-07-05T17:57:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/c1-esterase-inhibitor-human-octapharma-hereditary-angioedema-hae-c1-esterase-inhibitor-c1-inh-deficiency-likelihood-of-approval/ 2025-01-21T01:32:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mze-829-maze-therapeutics-chronic-kidney-disease-chronic-renal-failure-likelihood-of-approval/ 2024-01-23T01:04:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dnl-126-denali-therapeutics-mucopolysaccharidosis-iii-mps-iii-sanfilippo-syndrome-likelihood-of-approval/ 2024-01-23T01:03:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sefa-1024-northsea-therapeutics-hypertriglyceridemia-likelihood-of-approval/ 2025-01-21T01:31:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tak-881-takeda-pharmaceutical-primary-immune-deficiency-pid-likelihood-of-approval/ 2025-01-21T01:31:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/valacyclovir-hyloris-pharmaceuticals-viral-infections-likelihood-of-approval/ 2025-01-21T01:31:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bi-905711-boehringer-ingelheim-international-metastatic-adenocarcinoma-of-the-pancreas-likelihood-of-approval/ 2024-07-05T17:57:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sar-444336-sanofi-inflammation-likelihood-of-approval/ 2024-01-23T01:01:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ava-6000-avacta-life-sciences-malignant-fibrous-histiocytoma-likelihood-of-approval/ 2025-01-21T01:31:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anpa-0073-schrodinger-pulmonary-arterial-hypertension-likelihood-of-approval/ 2025-01-21T01:31:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ion-717-ionis-pharmaceuticals-neurodegenerative-diseases-likelihood-of-approval/ 2024-01-23T00:59:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gsk-101-gsk-solid-tumor-likelihood-of-approval/ 2024-05-20T04:51:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/senl-101-hebei-senlang-biotechnology-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-21T01:31:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/senl-101-hebei-senlang-biotechnology-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-21T01:31:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pbft-02-passage-bio-frontotemporal-dementia-ftd-likelihood-of-approval/ 2024-09-09T05:04:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lb-102-lb-pharmaceuticals-schizophrenia-likelihood-of-approval/ 2024-09-09T05:04:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adclec-syn1-car-t-cells-takeda-pharmaceutical-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2024-01-23T00:56:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adclec-syn1-car-t-cells-takeda-pharmaceutical-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2024-01-23T00:56:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/st-100-stuart-therapeutics-keratoconjunctivitis-sicca-dry-eye-likelihood-of-approval/ 2024-01-23T00:54:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lbpec-01-locus-biosciences-escherichia-coli-infections-likelihood-of-approval/ 2024-01-23T00:53:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ad-17002-advagene-biopharma-asthma-likelihood-of-approval/ 2025-01-21T01:31:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/barzolvolimab-celldex-therapeutics-chronic-urticaria-or-hives-likelihood-of-approval/ 2025-01-21T01:31:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mrg-003-shanghai-miracogen-adenocarcinoma-of-the-gastroesophageal-junction-likelihood-of-approval/ 2025-01-21T01:31:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/irinotecan-hydrochloride-cspc-pharmaceutical-group-metastatic-pancreatic-cancer-likelihood-of-approval/ 2025-01-21T01:31:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/volrustomig-astrazeneca-leiomyosarcoma-likelihood-of-approval/ 2025-01-21T01:31:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/volrustomig-astrazeneca-pleomorphic-liposarcoma-likelihood-of-approval/ 2025-01-21T01:31:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mrg-003-shanghai-miracogen-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-21T01:31:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/apg-157-aveta-biomics-high-grade-glioma-likelihood-of-approval/ 2025-01-21T01:30:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/liv-001-liveome-ulcerative-colitis-likelihood-of-approval/ 2025-01-21T01:30:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/volrustomig-astrazeneca-rhabdomyosarcoma-likelihood-of-approval/ 2025-01-21T01:30:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/apg-157-aveta-biomics-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2025-01-21T01:30:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/apg-157-aveta-biomics-oligodendroglioma-likelihood-of-approval/ 2025-01-21T01:30:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/apg-157-aveta-biomics-gliosarcoma-likelihood-of-approval/ 2025-01-21T01:30:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/apg-157-aveta-biomics-anaplastic-astrocytoma-likelihood-of-approval/ 2025-01-21T01:30:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/talquetamab-johnson-johnson-multiple-myeloma-kahler-disease-likelihood-of-approval/ 2025-01-21T01:30:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/theophylline-cyrano-therapeutics-hyposmia-likelihood-of-approval/ 2025-01-21T01:30:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/penpulimab-akeso-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-21T01:30:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/inkmune-inmune-bio-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2024-09-09T05:04:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/serclutamab-talirine-abbvie-esophageal-cancer-likelihood-of-approval/ 2024-05-20T04:50:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/serclutamab-talirine-abbvie-bladder-carcinoma-likelihood-of-approval/ 2024-05-20T04:50:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/serclutamab-talirine-abbvie-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2024-05-20T04:50:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/serclutamab-talirine-abbvie-cervical-cancer-likelihood-of-approval/ 2024-05-20T04:49:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/serclutamab-talirine-abbvie-sarcomas-likelihood-of-approval/ 2024-05-20T04:50:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/serclutamab-talirine-abbvie-kidney-cancer-renal-cell-cancer-likelihood-of-approval/ 2024-05-20T04:50:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/serclutamab-talirine-abbvie-colorectal-cancer-likelihood-of-approval/ 2024-05-20T04:49:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/izalontamab-systimmune-esophageal-squamous-cell-carcinoma-escc-likelihood-of-approval/ 2025-01-21T01:30:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/izalontamab-systimmune-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2025-01-21T01:30:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adebrelimab-jiangsu-hengrui-medicine-pancreatic-cancer-likelihood-of-approval/ 2025-01-21T01:30:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bt-7480-bicycle-therapeutics-cervical-cancer-likelihood-of-approval/ 2025-01-21T01:29:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bt-7480-bicycle-therapeutics-anal-cancer-likelihood-of-approval/ 2025-01-21T01:30:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bt-5528-bicycle-therapeutics-ovarian-cancer-likelihood-of-approval/ 2025-01-21T01:29:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bt-5528-bicycle-therapeutics-bladder-cancer-likelihood-of-approval/ 2025-01-21T01:29:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/obecabtagene-autoleucel-autolus-therapeutics-primary-mediastinal-b-cell-lymphoma-likelihood-of-approval/ 2025-01-21T01:29:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/esepapogene-zalarnarepvec-hookipa-pharma-oropharyngeal-cancer-likelihood-of-approval/ 2025-01-21T01:29:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/obecabtagene-autoleucel-autolus-therapeutics-burkitt-lymphoma-likelihood-of-approval/ 2025-01-21T01:29:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rifaximin-ssd-bausch-health-sickle-cell-disease-likelihood-of-approval/ 2024-05-20T04:49:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/budigalimab-abbvie-metastatic-hepatocellular-carcinoma-hcc-likelihood-of-approval/ 2025-01-21T01:29:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dersimelagon-phosphate-mitsubishi-tanabe-pharma-porphyria-erythropoietic-protoporphyri-likelihood-of-approval/ 2024-07-05T17:56:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cdx-1140-celldex-therapeutics-peritoneal-cancer-likelihood-of-approval/ 2024-09-09T05:04:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cdx-1140-celldex-therapeutics-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-09-09T05:04:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cdx-1140-celldex-therapeutics-endometrial-cancer-likelihood-of-approval/ 2024-09-09T05:04:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cdx-1140-celldex-therapeutics-fallopian-tube-cancer-likelihood-of-approval/ 2024-09-09T05:04:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/afm-24i-affimed-metastatic-colorectal-cancer-likelihood-of-approval/ 2025-01-21T01:29:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/voyager-v1-vyriad-solid-tumor-likelihood-of-approval/ 2025-01-21T01:29:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lemtrada-sanofi-primary-progressive-multiple-sclerosis-ppms-likelihood-of-approval/ 2024-01-22T17:50:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/afm-24i-affimed-esophageal-cancer-likelihood-of-approval/ 2025-01-21T01:29:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/afm-24i-affimed-transitional-cell-cancer-urothelial-cell-cancer-likelihood-of-approval/ 2025-01-21T01:29:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/afm-24i-affimed-adenocarcinoma-of-the-gastroesophageal-junction-likelihood-of-approval/ 2025-01-21T01:29:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/afm-24i-affimed-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2025-01-21T01:29:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/afm-24i-affimed-renal-cell-carcinoma-likelihood-of-approval/ 2025-01-21T01:29:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/afm-24i-affimed-head-and-neck-cancer-likelihood-of-approval/ 2025-01-21T01:28:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/afm-24i-affimed-pancreatic-cancer-likelihood-of-approval/ 2025-01-21T01:28:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/afm-24i-affimed-gastric-cancer-likelihood-of-approval/ 2025-01-21T01:28:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/afm-24i-affimed-ovarian-cancer-likelihood-of-approval/ 2025-01-21T01:28:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/afm-24i-affimed-cervical-cancer-likelihood-of-approval/ 2025-01-21T01:28:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mupadolimab-corvus-pharmaceuticals-uterine-cancer-likelihood-of-approval/ 2025-01-21T01:28:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mupadolimab-corvus-pharmaceuticals-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2025-01-21T01:28:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mupadolimab-corvus-pharmaceuticals-sarcomas-likelihood-of-approval/ 2025-01-21T01:28:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mupadolimab-corvus-pharmaceuticals-endometrial-cancer-likelihood-of-approval/ 2025-01-21T01:28:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mupadolimab-corvus-pharmaceuticals-kidney-cancer-renal-cell-cancer-likelihood-of-approval/ 2025-01-21T01:28:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mupadolimab-corvus-pharmaceuticals-colorectal-cancer-likelihood-of-approval/ 2025-01-21T01:28:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mupadolimab-corvus-pharmaceuticals-cervical-cancer-likelihood-of-approval/ 2025-01-21T01:28:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mupadolimab-corvus-pharmaceuticals-bladder-cancer-likelihood-of-approval/ 2025-01-21T01:28:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/patritumab-deruxtecan-daiichi-sankyo-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-21T01:28:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ciforadenant-corvus-pharmaceuticals-endometrial-cancer-likelihood-of-approval/ 2025-01-21T01:27:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ciforadenant-corvus-pharmaceuticals-uterine-cancer-likelihood-of-approval/ 2025-01-21T01:27:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ciforadenant-corvus-pharmaceuticals-cervical-cancer-likelihood-of-approval/ 2025-01-21T01:27:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ciforadenant-corvus-pharmaceuticals-sarcomas-likelihood-of-approval/ 2025-01-21T01:27:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/repotrectinib-bristol-myers-squibb-non-small-cell-lung-carcinoma-likelihood-of-approval/ 2025-01-21T01:27:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/deucravacitinib-bristol-myers-squibb-hidradenitis-suppurativa-likelihood-of-approval/ 2025-01-21T01:27:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/danburstotug-immuneoncia-therapeutics-metastatic-melanoma-likelihood-of-approval/ 2024-06-19T06:04:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cetuximab-biobetter-shanghai-henlius-biotech-adenocarcinoma-of-the-gastroesophageal-junction-likelihood-of-approval/ 2025-01-21T01:27:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pep-010-pep-therapy-metastatic-ovarian-cancer-likelihood-of-approval/ 2025-01-21T01:27:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cetuximab-biobetter-shanghai-henlius-biotech-gastric-cancer-likelihood-of-approval/ 2025-01-21T01:27:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ba-3182-bioatla-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-21T01:27:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ba-3182-bioatla-adenocarcinoma-likelihood-of-approval/ 2025-01-21T01:27:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ba-3182-bioatla-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2025-01-21T01:27:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ba-3182-bioatla-colon-cancer-likelihood-of-approval/ 2025-01-21T01:26:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ba-3182-bioatla-pancreatic-cancer-likelihood-of-approval/ 2025-01-21T01:27:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ba-3182-bioatla-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-21T01:27:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/torsemide-er-sarfez-pharmaceuticals-congestive-heart-failure-heart-failure-likelihood-of-approval/ 2025-01-21T01:26:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ba-3182-bioatla-prostate-cancer-likelihood-of-approval/ 2025-01-21T01:26:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ba-3182-bioatla-colorectal-cancer-likelihood-of-approval/ 2025-01-21T01:26:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/erfonrilimab-alphamab-oncology-thymic-carcinoma-likelihood-of-approval/ 2025-01-21T01:26:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/erfonrilimab-alphamab-oncology-colorectal-cancer-likelihood-of-approval/ 2025-01-21T01:26:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/virios-to-advance-development-for-long-covid-combination-therapy/ 2024-01-22T17:30:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ttp-273-vtv-therapeutics-type-2-diabetes-likelihood-of-approval/ 2024-01-22T17:28:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mesocancervac-amphera-malignant-mesothelioma-likelihood-of-approval/ 2025-01-21T01:26:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sct-200-sinocelltech-group-colorectal-cancer-likelihood-of-approval/ 2025-01-21T01:26:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/balstilimab-agenus-oropharyngeal-cancer-likelihood-of-approval/ 2025-01-21T01:26:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lidocaine-hydrochloride-scilex-holding-neck-pain-cervicalgia-likelihood-of-approval/ 2024-09-09T05:03:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/enamptcumab-aqualung-therapeutics-lung-injury-likelihood-of-approval/ 2024-01-22T17:25:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zandatrigine-neurocrine-biosciences-epileptic-encephalopathy-likelihood-of-approval/ 2024-01-22T17:25:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/leu-001-leucid-bio-recurrent-head-and-neck-squamous-cell-carcinoma-likelihood-of-approval/ 2024-01-22T17:24:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/efgartigimod-alfa-argenx-tachycardia-tachyarrhythmias-likelihood-of-approval/ 2025-01-21T01:26:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/efgartigimod-alfa-argenx-immune-mediated-necrotizing-myopathy-imnm-likelihood-of-approval/ 2025-01-21T01:26:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cbt-npc-cha-biotech-parkinson-s-disease-likelihood-of-approval/ 2025-01-21T01:26:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tinostamustine-mundipharma-edo-mycosis-fungoides-likelihood-of-approval/ 2025-01-21T01:26:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/upadacitinib-er-abbvie-vitiligo-likelihood-of-approval/ 2025-01-21T01:26:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tinostamustine-mundipharma-edo-sezary-syndrome-likelihood-of-approval/ 2025-01-21T01:26:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pr-15-advancecor-peripheral-arterial-disease-pad-peripheral-vascular-disease-pvd-likelihood-of-approval/ 2025-01-21T01:25:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/durvalumab-astrazeneca-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2025-01-21T01:25:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sacituzumab-govitecan-gilead-sciences-fallopian-tube-cancer-likelihood-of-approval/ 2025-01-21T01:25:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sacituzumab-govitecan-gilead-sciences-peritoneal-cancer-likelihood-of-approval/ 2025-01-21T01:25:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zeripatamig-light-chain-bioscience-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2025-01-21T01:25:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/itacitinib-adipate-incyte-chronic-myelomonocytic-leukemia-cmml-likelihood-of-approval/ 2025-01-21T01:25:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zeripatamig-light-chain-bioscience-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2025-01-21T01:25:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dostarlimab-gsk-oral-cavity-mouth-cancer-likelihood-of-approval/ 2025-01-21T01:25:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atezolizumab-f-hoffmann-la-roche-chondrosarcoma-likelihood-of-approval/ 2025-01-21T01:25:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/me-344-mei-pharma-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2025-01-21T01:25:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dostarlimab-gsk-hypopharyngeal-cancer-likelihood-of-approval/ 2025-01-21T01:25:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dostarlimab-gsk-laryngeal-cancer-likelihood-of-approval/ 2025-01-21T01:25:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dostarlimab-gsk-oropharyngeal-cancer-likelihood-of-approval/ 2025-01-21T01:25:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/incvax-immunophotonics-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-21T01:24:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/incvax-immunophotonics-soft-tissue-sarcoma-likelihood-of-approval/ 2025-01-21T01:25:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/incvax-immunophotonics-melanoma-likelihood-of-approval/ 2025-01-21T01:24:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/incvax-immunophotonics-solid-tumor-likelihood-of-approval/ 2025-01-21T01:24:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lirilumab-bristol-myers-squibb-muscle-invasive-bladder-cancer-mibc-likelihood-of-approval/ 2025-01-21T01:24:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/solriamfetol-hydrochloride-axsome-therapeutics-major-depressive-disorder-likelihood-of-approval/ 2025-01-21T01:24:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fadraciclib-cyclacel-pharmaceuticals-cervical-cancer-likelihood-of-approval/ 2025-01-21T01:24:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fadraciclib-cyclacel-pharmaceuticals-squamous-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-21T01:24:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tradipitant-vanda-pharmaceuticals-functional-non-ulcer-dyspepsia-likelihood-of-approval/ 2025-01-21T01:24:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trabectedin-pharma-mar-myxoid-liposarcoma-likelihood-of-approval/ 2025-01-21T01:24:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trabectedin-pharma-mar-round-cell-liposarcoma-likelihood-of-approval/ 2025-01-21T01:24:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dupilumab-regeneron-pharmaceuticals-immunoglobulin-g4-related-disease-igg4-rd-likelihood-of-approval/ 2025-01-21T01:24:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trabectedin-pharma-mar-dedifferentiated-liposarcoma-likelihood-of-approval/ 2025-01-21T01:24:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-bristol-myers-squibb-hypopharyngeal-cancer-likelihood-of-approval/ 2025-01-21T01:23:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-bristol-myers-squibb-laryngeal-cancer-likelihood-of-approval/ 2025-01-21T01:24:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abemaciclib-eli-lilly-and-co-endometrial-cancer-likelihood-of-approval/ 2025-01-21T01:24:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/udenafil-mezzion-pharma-liver-diseases-likelihood-of-approval/ 2025-01-21T01:23:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-bristol-myers-squibb-penile-cancer-likelihood-of-approval/ 2025-01-21T01:23:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-bristol-myers-squibb-salivary-gland-cancer-likelihood-of-approval/ 2025-01-21T01:23:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/alirocumab-sanofi-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-09-09T05:01:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/immune-globulin-human-octapharma-neuropathy-likelihood-of-approval-2/ 2024-12-25T19:24:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anifrolumab-astrazeneca-vitiligo-likelihood-of-approval-2/ 2024-12-25T19:24:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lb-100-lixte-biotechnology-synovial-sarcoma-likelihood-of-approval-2/ 2024-12-25T19:24:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lb-100-lixte-biotechnology-myxoid-liposarcoma-likelihood-of-approval-2/ 2024-12-25T19:24:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lb-100-lixte-biotechnology-pleomorphic-liposarcoma-likelihood-of-approval-2/ 2024-12-25T19:24:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lb-100-lixte-biotechnology-fibrosarcoma-likelihood-of-approval-2/ 2024-12-25T19:24:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lb-100-lixte-biotechnology-soft-tissue-sarcoma-likelihood-of-approval-2/ 2024-12-25T19:24:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lb-100-lixte-biotechnology-nerve-sheath-tumor-likelihood-of-approval-2/ 2024-12-25T19:24:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lb-100-lixte-biotechnology-leiomyosarcoma-likelihood-of-approval-2/ 2024-12-25T19:24:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ropeginterferon-alfa-2b-la-pharmaessentia-hepatitis-b-likelihood-of-approval-2/ 2024-12-25T19:24:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cdx-301-celldex-therapeutics-skin-cancer-likelihood-of-approval-2/ 2024-12-25T19:24:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cdx-301-celldex-therapeutics-triple-negative-breast-cancer-tnbc-likelihood-of-approval-2/ 2024-12-25T19:24:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/fda-rejects-astellas-gastric-cancer-drug-application/ 2024-01-22T17:00:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ramucirumab-eli-lilly-and-co-recurrent-head-and-neck-squamous-cell-carcinoma-likelihood-of-approval-2/ 2024-12-25T19:23:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/niraparib-gsk-oropharyngeal-cancer-likelihood-of-approval/ 2025-01-21T01:21:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/niraparib-gsk-oral-cavity-mouth-cancer-likelihood-of-approval/ 2025-01-21T01:22:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/navitoclax-dihydrochloride-abbvie-myelodysplastic-syndrome-likelihood-of-approval/ 2025-01-21T01:22:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fibromun-philogen-soft-tissue-sarcoma-likelihood-of-approval/ 2025-01-21T01:22:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fibromun-philogen-leiomyosarcoma-likelihood-of-approval/ 2025-01-21T01:22:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ramucirumab-eli-lilly-and-co-laryngeal-cancer-likelihood-of-approval-2/ 2024-12-25T19:23:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ramucirumab-eli-lilly-and-co-oropharyngeal-cancer-likelihood-of-approval-2/ 2024-12-25T19:23:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ramucirumab-eli-lilly-and-co-oral-cavity-mouth-cancer-likelihood-of-approval-2/ 2024-12-25T19:23:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sh-105-shorla-oncology-breast-cancer-likelihood-of-approval/ 2024-02-08T19:27:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/crizotinib-pfizer-triple-negative-breast-cancer-tnbc-likelihood-of-approval-2/ 2024-12-25T19:23:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ramucirumab-eli-lilly-and-co-hypopharyngeal-cancer-likelihood-of-approval-2/ 2024-12-25T19:23:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/crizotinib-pfizer-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval-2/ 2024-12-25T19:23:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/selumetinib-sulfate-astrazeneca-peripheral-nerve-sheath-tumor-neurofibrosarcoma-likelihood-of-approval/ 2025-01-21T01:22:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/niraparib-gsk-laryngeal-cancer-likelihood-of-approval/ 2025-01-21T01:21:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/edivoxetine-hydrochloride-eli-lilly-and-co-attention-deficit-hyperactivity-disorder-adhd-likelihood-of-approval/ 2024-01-23T09:38:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/alemtuzumab-sanofi-t-cell-leukemia-likelihood-of-approval/ 2025-01-21T01:21:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/axitinib-pfizer-salivary-gland-cancer-likelihood-of-approval/ 2025-01-21T01:21:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/niraparib-gsk-hypopharyngeal-cancer-likelihood-of-approval/ 2025-01-21T01:21:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lenvatinib-mesylate-eisai-neuroendocrine-carcinoma-likelihood-of-approval/ 2025-01-21T01:21:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/forigerimod-acetate-immupharma-for-chronic-inflammatory-demyelinating-polyneuropathy-cidp-likelihood-of-approval/ 2024-01-23T06:01:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/processa-shoots-for-breast-cancer-label-expansion-for-capecitabine-combo/ 2024-01-22T15:51:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/cg-oncology-files-ipo/ 2024-01-22T15:17:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/oncology-2023-brand-launches/ 2024-01-22T13:04:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ose-shares-pipeline-updates-with-plans-phase-iii-trial-for-tedopi/ 2024-01-22T12:20:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/nhs-to-ramp-up-mmr-vaccine-drive-amid-surging-measles-cases-in-england/ 2024-01-22T11:44:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/obesity-drugs-could-fuel-the-next-pharma-cmo-gold-rush/ 2024-01-22T11:33:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/sandoz-acquire-coherus-cimerli/ 2024-01-22T10:43:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/nice-recommends-pfizer-talazoparib/ 2024-01-22T10:28:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-kyverna-multiple-sclerosis/ 2024-01-24T10:13:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/jj-fda-approval-balversa/ 2024-01-22T09:15:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/cdmos-pharmaceutical/ 2024-01-30T00:12:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/biotech-layoffs-strike-hard-with-pmv-pharma-ikena-and-bayer-sacking-staff/ 2024-01-19T17:24:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/nscf-embarks-on-fifth-flight-to-investigate-neurodegenerative-disorders-in-space/ 2024-01-25T11:25:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/delayed-diagnoses-in-gaucher-disease-patients/ 2024-01-19T14:19:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ikena-fires-35-of-staff-to-funnel-funds-into-clinical-oncology-programmes/ 2024-01-19T16:42:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-satsuma-migraine-treatment/ 2024-01-19T08:32:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-verastem-nsclc-therapy/ 2024-01-19T08:27:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/bridgebio-secures-funds/ 2024-01-19T08:25:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/argenx-vyvdura-approval-japan/ 2024-01-19T08:07:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/synendos-set-to-study-endocannabinoid-inhibitor-for-neuropsychiatric-conditions/ 2024-01-18T18:07:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/davos-ai-governance-alliance-calls-for-stronger-global-collaboration/ 2024-01-18T15:59:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/immatics-to-raise-175m-in-public-offering/ 2024-01-18T12:32:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/comanche-raises-75m-to-develop-preeclampsia-therapy/ 2024-02-01T09:20:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/xenetic-advance-dnase-programme/ 2024-01-18T10:48:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/windtree-licence-agreement-heart-failure/ 2024-01-18T10:31:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/sun-pharma-taro-pharmaceutical-acquisition/ 2024-01-18T09:09:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ratio-therapeutics-secures-funds/ 2024-01-18T09:05:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/interviews/bupa-is-leveraging-its-unique-position-to-develop-iot-and-ai-features/ 2024-01-19T16:34:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/coya-stretches-lead-drugs-development-to-parkinsons-and-dementia/ 2024-01-17T18:37:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/us-pto-voids-seagens-adc-patent-infringement-claims-against-daiichi/ 2024-01-17T17:16:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/ai-telemedicine-behavioural-health/ 2024-01-17T17:09:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/avoid-narrow-national-interest-in-fighting-next-pandemic-who-chief-says/ 2024-01-17T16:33:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/eu-access-to-oncology-medicines-lags-behind-in-the-netherlands/ 2024-01-17T13:02:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/stalica-raises-17-5m-to-advance-neurology-programmes/ 2024-01-17T16:37:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/kbi-biopharma-argonaut-alliance/ 2024-01-17T10:54:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-approves-vertex-gene-therapy/ 2024-01-24T10:11:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ec-grants-odd-precigen/ 2024-01-17T08:58:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/takeda-fda-approval-hyqvia-cidp/ 2024-01-17T09:00:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/roche-exec-says-more-pull-incentives-are-needed-to-tackle-amr/ 2024-01-17T16:54:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/allakos-cuts-employee-count-by-half-after-two-phase-ii-failures/ 2024-01-17T09:15:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ira-lawsuits-will-test-us-ability-to-regulate-social-pricing-in-pharma/ 2024-01-16T16:51:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/uk-mhra-announces-new-data-flagging-potential-valproate-risks/ 2024-01-16T13:26:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/biosenic-and-phebra-switch-up-terms-of-licensing-agreement/ 2024-01-16T11:50:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/abbvie-backed-disco-emerges-from-stealth-with-21-8m/ 2024-02-01T09:20:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/santhera-introduces-agamree-dmd/ 2024-01-16T11:25:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/roche-tecentriq-sc-ec-approval/ 2024-01-16T11:21:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/how-healthcare-providers-can-build-trust-with-consumers/ 2024-01-16T09:50:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/xnk-therapeutics-evencaleucel-ema/ 2024-01-16T08:55:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-neuraptive-therapeutics-ntx-001/ 2024-01-16T08:53:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/how-building-a-global-data-core-delivers-commercial-agility-for-the-future/ 2024-01-18T08:59:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/taiwan-fdi-to-china-drops-to-two-decade-low/ 2024-03-27T23:35:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/how-sovereign-wealth-funds-are-affecting-industries-and-macroeconomics/ 2024-03-27T23:35:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/drug-farm-candidate-gains-rare-paediatric-disease-status/ 2024-01-15T16:05:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/amgen-obesity-space-jpm24/ 2024-01-17T17:16:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/msds-keytruda-wins-expanded-fda-combo-approval-in-cervical-cancer/ 2024-01-16T15:11:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/basilea-buys-spexis-preclinical-antibiotics-programme-for-2-3m/ 2024-01-15T12:08:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/pcm-trials-acquires-netherlands-based-clinical-trial-service/ 2025-09-22T12:49:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-yet-to-find-link-between-suicidal-risk-and-glp-1ra-use/ 2024-01-12T16:14:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/obesity-disease-management/ 2024-07-01T10:36:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/emergent-wins-235-8m-us-defence-contract-for-anthrax-vaccine/ 2024-01-12T12:42:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/santheras-agamree-becomes-first-approved-treatment-in-uk-for-all-dmd-patients/ 2024-01-12T15:17:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/dermavant-announces-positive-data-from-phase-iii-atopic-dermatitis-trials/ 2024-01-12T14:53:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ji-xing-biogen-biib131/ 2024-01-12T11:29:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/clinchoice-csi-medical-acquisition/ 2024-01-12T10:15:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/cereno-cordenpharma-cs1/ 2024-01-12T09:07:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/syntheticgestalt-enamine-drug-discovery/ 2024-01-12T09:04:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/interviews/qa-exploring-the-challenges-behind-oncology-trials/ 2024-01-11T19:47:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tsha-102-taysha-gene-therapies-net-present-value/ 2024-06-13T18:49:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/crizotinib-pfizer-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2025-01-21T01:22:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/crizotinib-pfizer-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2025-01-21T01:22:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ramucirumab-eli-lilly-and-co-hypopharyngeal-cancer-likelihood-of-approval/ 2025-01-21T01:22:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ramucirumab-eli-lilly-and-co-laryngeal-cancer-likelihood-of-approval/ 2025-01-21T01:22:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ramucirumab-eli-lilly-and-co-oropharyngeal-cancer-likelihood-of-approval/ 2025-01-21T01:22:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ramucirumab-eli-lilly-and-co-oral-cavity-mouth-cancer-likelihood-of-approval/ 2025-01-21T01:22:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ramucirumab-eli-lilly-and-co-recurrent-head-and-neck-squamous-cell-carcinoma-likelihood-of-approval/ 2025-01-21T01:22:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cdx-301-celldex-therapeutics-skin-cancer-likelihood-of-approval/ 2025-01-21T01:22:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cdx-301-celldex-therapeutics-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2025-01-21T01:22:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ropeginterferon-alfa-2b-la-pharmaessentia-hepatitis-b-likelihood-of-approval/ 2025-01-21T01:23:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/teverelix-antev-benign-prostatic-hyperplasia-likelihood-of-approval/ 2024-06-19T06:02:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lb-100-lixte-biotechnology-soft-tissue-sarcoma-likelihood-of-approval/ 2025-01-21T01:23:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lb-100-lixte-biotechnology-nerve-sheath-tumor-likelihood-of-approval/ 2025-01-21T01:23:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lb-100-lixte-biotechnology-leiomyosarcoma-likelihood-of-approval/ 2025-01-21T01:23:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lb-100-lixte-biotechnology-myxoid-liposarcoma-likelihood-of-approval/ 2025-01-21T01:23:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lb-100-lixte-biotechnology-pleomorphic-liposarcoma-likelihood-of-approval/ 2025-01-21T01:23:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lb-100-lixte-biotechnology-fibrosarcoma-likelihood-of-approval/ 2025-01-21T01:23:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lb-100-lixte-biotechnology-synovial-sarcoma-likelihood-of-approval/ 2025-01-21T01:23:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/monalizumab-innate-pharma-small-cell-lung-cancer-likelihood-of-approval/ 2024-05-20T04:42:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anifrolumab-astrazeneca-vitiligo-likelihood-of-approval/ 2025-01-21T01:23:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kand-567-kancera-myocardial-infarction-likelihood-of-approval/ 2024-09-09T05:01:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/immune-globulin-human-octapharma-neuropathy-likelihood-of-approval/ 2025-01-21T01:23:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/umitrelimorgene-autodencel-immunomic-therapeutics-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-06-19T06:03:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/us-uk-strike-houthi-rebels-consequences-global-trade-fdi/ 2024-03-27T23:35:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/malaysia-singapore-strengthen-economic-ties/ 2024-03-27T23:35:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/monalizumab-astrazeneca-net-present-value/ 2024-07-02T02:11:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vincerinone-ptc-therapeutics-net-present-value/ 2024-06-13T18:55:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ligelizumab-novartis-net-present-value/ 2024-04-16T17:05:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ianalumab-novartis-net-present-value/ 2024-06-13T18:55:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rivunatpagene-miziparvovec-ultragenyx-pharmaceutical-net-present-value/ 2024-05-16T02:09:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kite-222-gilead-sciences-net-present-value/ 2024-07-02T02:04:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azd-2693-astrazeneca-net-present-value/ 2024-01-22T16:44:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tak-881-takeda-pharmaceutical-net-present-value/ 2024-12-13T02:53:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/olanzapine-er-teva-pharmaceutical-industries-net-present-value/ 2024-06-13T18:47:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-approves-import-of-french-drug-for-syphilis-amidst-wider-drug-shortages/ 2024-01-11T18:34:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/european-commission-greenlights-miratis-krazati-in-kras-mutated-nsclc/ 2024-01-11T17:44:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/eli-lilly-innovent-mazdutide/ 2024-01-11T15:43:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/five-key-factors-to-consider-when-selecting-a-granulation-system-for-tablet-manufacturing/ 2024-01-17T11:32:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/nice-expands-access-of-paxlovid-to-further-1-4-million-covid-19-patients/ 2024-01-11T11:58:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/bridgebio-gears-up-for-fda-review-of-acoramidis-following-phase-iii-results/ 2024-01-11T15:29:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/evotec-crohns-ibd-therapies/ 2024-01-11T11:03:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/3m-grant-wound-us/ 2024-01-11T11:00:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/gsks-nucala-china/ 2024-01-11T09:34:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/myrobalan-therapeutics-secures-funding/ 2024-01-11T09:32:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/stada-and-alvotechs-win-first-eu-approval-for-stelara-biosimilar/ 2024-01-10T17:08:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ema-approves-mitochon-neurogenerative-disease-study/ 2024-01-10T15:00:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/gsk-acquires-aiolos-bio-for-1-4bn-to-boost-respiratory-portfolio/ 2024-01-10T11:32:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/vertexs-casgevy-saudi/ 2024-01-10T11:23:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/alcons-dry-eye-drug-achieves-primary-endpoints-in-phase-iii-trials/ 2024-01-10T14:12:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/precision-tg-therapeutics-license-deal/ 2024-01-17T09:56:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/venatorx-menarini-deal-antibiotic/ 2024-01-10T09:11:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/bioarctic-ab-eisai-leqembi-approval-china/ 2024-01-10T09:14:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/switching-sales-investigating-the-financial-impacts-of-fdas-priority-vouchers/ 2024-01-17T15:18:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/excellence-awards/featured-company/2023-dispensense-navigroup/ 2024-02-22T09:25:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/fdi-deals-india-growing-economy-projects/ 2024-03-27T23:35:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-denies-approval-for-astellas-investigational-gastric-cancer-drug/ 2024-01-09T17:38:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/zealand-raises-dkr1-45bn-to-advance-obesity-pipeline/ 2024-01-09T17:51:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/msd-acquires-harpoon-for-680m-to-strengthen-t-cell-engager-armoury/ 2024-01-09T12:41:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/biocytogen-radiance-drug/ 2024-01-09T11:41:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/bios-health-precision-medicine-centre/ 2024-01-09T10:21:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ec-approves-pfizer-talzenna/ 2024-01-09T09:06:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/johnson-and-johnson-ambrx/ 2024-01-09T08:59:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hh-006-huahui-health-hepatitis-d-likelihood-of-approval/ 2024-07-05T06:29:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/subasumstat-takeda-pharmaceutical-relapsed-multiple-myeloma-likelihood-of-approval/ 2024-01-08T18:34:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aur-101-aurigene-oncology-psoriatic-arthritis-likelihood-of-approval/ 2024-03-18T23:38:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aur-101-aurigene-oncology-ankylosing-spondylitis-bekhterev-s-disease-likelihood-of-approval/ 2024-03-18T23:38:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/masct-hengrui-yuanzheng-biotechnology-ureter-cancer-likelihood-of-approval/ 2024-06-14T04:04:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/masct-hengrui-yuanzheng-biotechnology-metastatic-colorectal-cancer-likelihood-of-approval/ 2024-06-14T04:04:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/masct-hengrui-yuanzheng-biotechnology-kidney-cancer-renal-cell-cancer-likelihood-of-approval/ 2024-06-14T04:04:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/masct-hengrui-yuanzheng-biotechnology-soft-tissue-sarcoma-likelihood-of-approval/ 2025-01-20T02:11:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/masct-hengrui-yuanzheng-biotechnology-solid-tumor-likelihood-of-approval/ 2024-06-14T04:04:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/syd-4228-byondis-follicular-lymphoma-likelihood-of-approval/ 2024-09-09T02:19:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/syd-4228-byondis-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2024-09-09T02:19:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/syd-4228-byondis-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2024-09-09T02:19:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/senti-bio-cuts-37-of-workforce-to-free-funds-for-cell-therapy-cancer-trials/ 2024-01-08T16:09:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/berdazimer-sodium-nvn-liquidation-net-present-value/ 2024-01-08T17:30:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/sustainability-in-milling-a-greener-future-for-2024/ 2024-07-24T10:37:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/curevo-looks-to-challenge-gsks-shingrix-with-positive-phase-ii-data/ 2024-01-08T15:13:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/novartis-fda-pluvicto-plant/ 2024-01-08T11:03:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-florida-import-medicines/ 2024-01-08T10:39:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/boehringer-kyowa-licence-deal/ 2024-01-08T09:23:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-ligand-molluscum-contagiosum/ 2024-01-08T09:25:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/novo-nordisk-spends-up-to-1-64bn-on-us-biotech-startups/ 2024-01-08T00:01:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/saudi-fdi-inflows-rise-q3-2023/ 2024-03-27T23:35:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/amyriad-leaves-no-leaf-unturned-with-upcoming-phase-iii-alzheimers-trials/ 2024-01-05T21:07:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/signal-uk-online-pharmacies-selling-prescription-drugs-without-proper-checks/ 2024-01-05T18:16:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/intellia-propels-into-2024-with-crispr-pipeline-updates/ 2024-01-08T11:10:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/insilico-teams-up-with-menarini-for-breast-cancer-kat6-inhibitor/ 2024-01-05T16:47:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/moma-roche-cancer-drug/ 2024-01-05T11:23:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/abbvie-umoja-therapies-cancer/ 2024-01-05T11:20:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/excellence-awards/featured-company/2023-kai/ 2024-02-22T09:25:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/rhythm-expands-obesity-portfolio-with-phase-ii-weight-loss-drug-for-100m/ 2024-01-05T15:02:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/boehringer-3t-cancer-immunotherapies/ 2024-01-05T09:15:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/avistone-drug-financing/ 2024-01-05T08:44:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/osteoarthritis-purecell-group-osteoarthritis-likelihood-of-approval/ 2024-07-05T17:52:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ilyx-002-iolyx-therapeutics-keratoconjunctivitis-sicca-dry-eye-likelihood-of-approval/ 2025-01-21T01:21:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/triple-combination-therapy-novartis-malaria-likelihood-of-approval/ 2024-01-05T00:44:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brainshuttle-bs-cd20-multiple-sclerosis-genentech-usa-multiple-sclerosis-likelihood-of-approval/ 2024-01-05T00:44:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jnj-88549968-johnson-johnson-myeloproliferative-disorders-likelihood-of-approval/ 2024-01-24T19:31:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sgn-516-sgn-nanopharma-diabetic-neuropathy-likelihood-of-approval/ 2024-01-05T00:43:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mp-204-mustafa-nevzat-ilac-ve-kimyevi-maddeler-san-tic-human-papillomavirus-infections-likelihood-of-approval/ 2024-01-05T00:43:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/st-617-supportive-therapeutics-chemotherapy-induced-oral-mucositis-likelihood-of-approval/ 2024-07-05T17:52:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tbo-309-heart-research-institute-acute-ischemic-stroke-likelihood-of-approval/ 2024-01-05T00:42:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ceftibuten-xeruborbactam-qpex-biopharma-pyelonephritis-likelihood-of-approval/ 2025-01-21T01:21:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pneumococcal-monovalent-vaccine-pfizer-streptococcal-pneumonia-likelihood-of-approval/ 2024-01-05T00:42:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgb-43395-beigene-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2025-01-21T01:21:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgb-43395-beigene-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-21T01:21:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgb-43395-beigene-solid-tumor-likelihood-of-approval/ 2025-01-21T01:21:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bx-001n-bilix-ischemia-reperfusion-injury-likelihood-of-approval/ 2025-01-21T01:20:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azd-6912-astrazeneca-rheumatoid-arthritis-likelihood-of-approval/ 2024-09-09T05:00:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azd-5851-astrazeneca-hepatocellular-carcinoma-likelihood-of-approval/ 2024-02-22T01:12:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/r-01-hangzhou-neoantigen-therapeutics-gastric-cancer-likelihood-of-approval/ 2024-07-05T17:52:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mesenchymal-stem-cell-msc-cell-energy-life-sciences-group-human-immunodeficiency-virus-hiv-infections-aids-likelihood-of-approval/ 2025-01-21T01:20:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bl-0020-shanghai-best-link-bioscience-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-01-24T19:31:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bl-0020-shanghai-best-link-bioscience-small-cell-lung-cancer-likelihood-of-approval/ 2024-01-24T19:31:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bl-0020-shanghai-best-link-bioscience-pancreatic-cancer-likelihood-of-approval/ 2024-01-24T19:31:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dlx-001-delix-therapeutics-treatment-resistant-depression-likelihood-of-approval/ 2024-01-05T00:38:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dlx-001-delix-therapeutics-major-depressive-disorder-likelihood-of-approval/ 2025-01-21T01:20:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/db-1311-biontech-solid-tumor-likelihood-of-approval/ 2025-01-21T01:20:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ibi-130-innovent-biologics-solid-tumor-likelihood-of-approval/ 2024-06-19T06:01:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/teb-17231-280bio-solid-tumor-likelihood-of-approval/ 2024-04-20T01:19:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tl-925-telios-pharma-allergic-conjunctivitis-likelihood-of-approval/ 2024-04-20T01:19:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ckd-846-chong-kun-dang-pharmaceutical-benign-prostatic-hyperplasia-likelihood-of-approval/ 2024-01-05T00:36:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abbv-932-abbvie-bipolar-disorder-manic-depression-likelihood-of-approval/ 2024-06-19T06:01:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ahb-137-ausper-biopharma-hepatitis-b-likelihood-of-approval/ 2024-09-09T05:00:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ceacam5-sanofi-metastatic-colorectal-cancer-likelihood-of-approval/ 2024-01-05T00:35:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ceacam5-sanofi-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-01-05T00:35:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pf-07915234-pfizer-herpes-zoster-shingles-likelihood-of-approval/ 2025-01-21T01:20:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/exe-346-exegi-pharma-pouchitis-likelihood-of-approval/ 2024-01-05T00:34:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/probenecid-aphiotx-opium-withdrawal-syndrome-likelihood-of-approval/ 2024-01-05T00:34:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ves-001-vesper-bio-frontotemporal-dementia-ftd-likelihood-of-approval/ 2024-01-05T00:33:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/caba-201-cabaletta-bio-immune-mediated-necrotizing-myopathy-imnm-likelihood-of-approval/ 2025-01-21T01:20:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/caba-201-cabaletta-bio-dermatomyositis-likelihood-of-approval/ 2025-01-21T01:20:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/caba-201-cabaletta-bio-idiopathic-inflammatory-myopathy-iim-likelihood-of-approval/ 2025-01-21T01:20:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cd19-car-t-utc-therapeutics-lymphoma-likelihood-of-approval/ 2024-04-20T01:19:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/qn-01-qnovia-smoking-cessation-likelihood-of-approval/ 2024-01-05T00:32:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ibi-343-innovent-biologics-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2024-07-05T17:52:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/200-s-series-novel-combinations-dopamine-pathway-alto-neuroscience-neurodegenerative-diseases-likelihood-of-approval/ 2025-01-21T01:20:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/snp-318-scineuro-pharmaceuticals-neurodegenerative-diseases-likelihood-of-approval/ 2024-01-05T00:30:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/qn-019a-hangzhou-qihan-biotechnology-b-cell-acute-lymphocytic-leukemia-b-cell-acute-lymphoblastic-leukaemia-likelihood-of-approval/ 2024-01-05T00:30:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azd-9574-astrazeneca-vulvar-cancer-likelihood-of-approval/ 2024-07-05T17:52:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azd-9574-astrazeneca-vaginal-cancer-likelihood-of-approval/ 2024-07-05T17:52:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azd-9574-astrazeneca-endometrial-cancer-likelihood-of-approval/ 2024-07-05T17:52:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azd-9574-astrazeneca-cervical-cancer-likelihood-of-approval/ 2024-07-05T17:52:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/oce-205-ocelot-bio-hepatorenal-syndrome-likelihood-of-approval/ 2024-07-05T17:52:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dfl-24412-dompe-farmaceutici-chronic-low-back-pain-clbp-likelihood-of-approval/ 2024-07-05T17:52:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/glpg-5201-galapagos-refractory-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2024-05-20T04:41:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/glpg-5201-galapagos-relapsed-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2024-05-20T04:40:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nmra-m4r-neumora-therapeutics-schizophrenia-likelihood-of-approval/ 2024-01-05T00:28:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rg-6319-genentech-usa-urinary-tract-infections-likelihood-of-approval/ 2024-01-05T00:27:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rg-6289-f-hoffmann-la-roche-alzheimer-s-disease-likelihood-of-approval/ 2025-01-21T01:20:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sgn-alpv-pfizer-testicular-cancer-likelihood-of-approval/ 2024-01-05T00:27:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sgn-alpv-pfizer-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-01-05T00:26:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sgn-alpv-pfizer-gastric-cancer-likelihood-of-approval/ 2024-01-05T00:26:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sgn-alpv-pfizer-cervical-cancer-likelihood-of-approval/ 2024-01-05T00:26:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sgn-alpv-pfizer-ovarian-cancer-likelihood-of-approval/ 2024-01-05T00:26:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ism-012042-insilico-medicine-inflammatory-bowel-disease-likelihood-of-approval/ 2024-04-20T01:18:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pf-07921188-biontech-herpes-zoster-shingles-likelihood-of-approval/ 2024-01-05T00:25:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ps-001-pharmasaga-type-2-diabetes-likelihood-of-approval/ 2024-01-05T00:25:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/225ac-psma-r2-novartis-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2024-02-08T04:34:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ima-203cd8-immatics-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2025-01-21T01:20:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ima-203cd8-immatics-squamous-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-21T01:20:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ima-203cd8-immatics-bladder-carcinoma-likelihood-of-approval/ 2025-01-21T01:20:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ima-203cd8-immatics-fibrosarcoma-likelihood-of-approval/ 2025-01-21T01:20:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ima-203cd8-immatics-thymic-carcinoma-likelihood-of-approval/ 2025-01-21T01:20:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ima-203cd8-immatics-rhabdomyosarcoma-likelihood-of-approval/ 2025-01-21T01:20:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ima-203cd8-immatics-esophageal-cancer-likelihood-of-approval/ 2025-01-21T01:19:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ima-203cd8-immatics-uterine-cancer-likelihood-of-approval/ 2025-01-21T01:19:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ima-203cd8-immatics-kidney-cancer-renal-cell-cancer-likelihood-of-approval/ 2025-01-21T01:19:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ima-203cd8-immatics-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-21T01:19:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ima-203cd8-immatics-ovarian-cancer-likelihood-of-approval/ 2025-01-21T01:19:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/alto-101-alto-neuroscience-cognitive-impairment-associated-with-schizophrenia-cias-likelihood-of-approval/ 2024-09-09T04:59:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mk-1084-merck-metastatic-colorectal-cancer-likelihood-of-approval/ 2025-01-21T01:19:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xs-005-xellsmart-biomedical-shanghai-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-01-05T00:19:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ly-3541860-eli-lilly-and-co-autoimmune-disorders-likelihood-of-approval/ 2025-01-21T01:19:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tyra-200-tyra-biosciences-solid-tumor-likelihood-of-approval/ 2024-06-19T06:01:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/luag-06474-h-lundbeck-pain-likelihood-of-approval/ 2025-01-21T01:19:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/codeine-dipyrone-eurofarma-laboratorios-post-operative-pain-likelihood-of-approval/ 2024-01-05T00:17:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vhx-896-vanda-pharmaceuticals-bipolar-i-disorder-likelihood-of-approval/ 2025-01-21T01:19:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jnj-4703-johnson-johnson-sicca-syndrome-sjogren-likelihood-of-approval/ 2024-01-05T00:16:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jnj-4703-johnson-johnson-rheumatoid-arthritis-likelihood-of-approval/ 2024-01-05T00:16:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jnj-4703-johnson-johnson-ulcerative-colitis-likelihood-of-approval/ 2024-01-05T00:16:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cls-001-cellusion-corneal-edema-likelihood-of-approval/ 2024-01-05T00:16:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/qls-31905-qilu-pharmaceutical-gallbladder-cancer-likelihood-of-approval/ 2024-01-24T19:31:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/qls-31905-qilu-pharmaceutical-pancreatic-cancer-likelihood-of-approval/ 2025-01-21T01:19:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pulmostem-amniotics-influenzavirus-a-infections-likelihood-of-approval/ 2025-01-21T01:19:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pulmostem-amniotics-respiratory-syncytial-virus-rsv-infections-likelihood-of-approval/ 2025-01-21T01:19:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rg-6035-genentech-usa-primary-progressive-multiple-sclerosis-ppms-likelihood-of-approval/ 2024-05-20T04:40:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/regn-5093m114-regeneron-pharmaceuticals-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-03-19T00:22:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zongertinib-boehringer-ingelheim-international-esophageal-cancer-likelihood-of-approval/ 2024-07-05T17:52:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zongertinib-boehringer-ingelheim-international-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-21T01:19:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zongertinib-boehringer-ingelheim-international-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2024-04-20T01:17:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zongertinib-boehringer-ingelheim-international-colorectal-cancer-likelihood-of-approval/ 2024-07-05T17:51:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sar-441566-sanofi-plaque-psoriasis-psoriasis-vulgaris-likelihood-of-approval/ 2025-01-21T01:19:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sar-441566-sanofi-inflammatory-bowel-disease-likelihood-of-approval/ 2025-01-21T01:19:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cd19-and-bcma-car-t-cells-shanghai-unicar-therapy-bio-medicine-technology-leukemia-likelihood-of-approval/ 2025-01-21T01:19:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hb-0034-huabo-biopharm-shanghai-systemic-lupus-erythematosus-likelihood-of-approval/ 2025-01-21T01:18:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hb-0034-huabo-biopharm-shanghai-ulcerative-colitis-likelihood-of-approval/ 2025-01-21T01:18:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dexborneol-edaravone-simcere-pharmaceutical-group-acute-ischemic-stroke-likelihood-of-approval/ 2025-01-21T01:18:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aqst-109-aquestive-therapeutics-anaphylaxis-likelihood-of-approval/ 2024-06-19T06:01:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lp-284-lantern-pharma-refractory-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2024-09-09T04:59:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lp-284-lantern-pharma-relapsed-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2024-09-09T04:59:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lp-284-lantern-pharma-b-cell-non-hodgkin-lymphoma-likelihood-of-approval/ 2024-09-09T04:59:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lp-284-lantern-pharma-mantle-cell-lymphoma-likelihood-of-approval/ 2024-09-09T04:59:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lp-284-lantern-pharma-solid-tumor-likelihood-of-approval/ 2024-09-09T04:59:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lp-284-lantern-pharma-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2024-09-09T04:59:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gene-therapy-to-target-cd19-for-hematological-tumors-chengdu-usino-technology-biology-b-cell-acute-lymphocytic-leukemia-b-cell-acute-lymphoblastic-leukaemia-likelihood-of-approval/ 2024-02-22T01:11:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gene-therapy-to-target-cd19-for-hematological-tumors-chengdu-usino-technology-biology-hematological-tumor-likelihood-of-approval/ 2024-02-22T01:11:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kt-333-kymera-therapeutics-kidney-cancer-renal-cell-cancer-likelihood-of-approval/ 2025-01-21T01:18:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kt-333-kymera-therapeutics-natural-killer-cell-lymphomas-likelihood-of-approval/ 2025-01-21T01:18:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kt-333-kymera-therapeutics-t-cell-lymphomas-likelihood-of-approval/ 2025-01-21T01:18:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kt-333-kymera-therapeutics-solid-tumor-likelihood-of-approval/ 2025-01-21T01:18:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kt-333-kymera-therapeutics-head-and-neck-cancer-likelihood-of-approval/ 2025-01-21T01:18:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kt-333-kymera-therapeutics-hodgkin-lymphoma-b-cell-hodgkin-lymphoma-likelihood-of-approval/ 2025-01-21T01:18:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kt-333-kymera-therapeutics-non-hodgkin-lymphoma-likelihood-of-approval/ 2025-01-21T01:18:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/snc-103-shanghai-simnova-biotechnology-refractory-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2024-09-09T04:59:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/snc-103-shanghai-simnova-biotechnology-relapsed-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2024-09-09T04:59:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/snc-103-shanghai-simnova-biotechnology-acute-lymphocytic-leukemia-all-acute-lymphoblastic-leukemia-likelihood-of-approval/ 2024-09-09T04:58:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/snc-103-shanghai-simnova-biotechnology-non-hodgkin-lymphoma-likelihood-of-approval/ 2024-09-09T04:58:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/senl-h19-hebei-senlang-biotechnology-b-cell-acute-lymphocytic-leukemia-b-cell-acute-lymphoblastic-leukaemia-likelihood-of-approval/ 2024-01-05T00:04:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lunsekimig-sanofi-asthma-likelihood-of-approval/ 2025-01-21T01:18:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tilpisertib-fosmecarbil-gilead-sciences-ulcerative-colitis-likelihood-of-approval/ 2024-04-20T01:16:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/si-101-sirpant-immunotherapeutics-nodal-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2024-09-09T04:58:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/si-101-sirpant-immunotherapeutics-refractory-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2024-09-09T04:58:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/si-101-sirpant-immunotherapeutics-relapsed-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2024-09-09T04:58:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/si-101-sirpant-immunotherapeutics-anaplastic-large-cell-lymphoma-alcl-likelihood-of-approval/ 2024-09-09T04:58:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/si-101-sirpant-immunotherapeutics-mycosis-fungoides-likelihood-of-approval/ 2024-09-09T04:58:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/si-101-sirpant-immunotherapeutics-angioimmunoblastic-t-cell-lymphoma-aitl-immunoblastic-lymphadenopathy-likelihood-of-approval/ 2024-09-09T04:58:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/si-101-sirpant-immunotherapeutics-sezary-syndrome-likelihood-of-approval/ 2024-09-09T04:58:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/si-101-sirpant-immunotherapeutics-cutaneous-t-cell-lymphoma-likelihood-of-approval/ 2024-09-09T04:58:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/si-101-sirpant-immunotherapeutics-follicular-lymphoma-likelihood-of-approval/ 2024-09-09T04:58:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/si-101-sirpant-immunotherapeutics-mantle-cell-lymphoma-likelihood-of-approval/ 2024-09-09T04:58:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/si-101-sirpant-immunotherapeutics-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2024-09-09T04:58:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lava-1223-pfizer-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-01-24T19:31:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nvl-655-nuvalent-inflammatory-myofibroblastic-tumor-imt-likelihood-of-approval/ 2024-04-20T01:15:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nvl-655-nuvalent-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-04-20T01:15:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nvl-520-nuvalent-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-01-04T23:59:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nvl-520-nuvalent-solid-tumor-likelihood-of-approval/ 2024-01-04T23:59:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abbv-1882-abbvie-human-immunodeficiency-virus-hiv-infections-aids-likelihood-of-approval/ 2024-07-05T17:51:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rmc-6236-revolution-medicines-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-21T01:18:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rmc-6236-revolution-medicines-solid-tumor-likelihood-of-approval/ 2025-01-21T01:18:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cd19-cd22-car-t-cells-shanghai-biomed-union-biotechnology-b-cell-acute-lymphocytic-leukemia-b-cell-acute-lymphoblastic-leukaemia-likelihood-of-approval/ 2024-01-04T23:58:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sc-291-sana-biotechnology-non-hodgkin-lymphoma-likelihood-of-approval/ 2024-09-09T04:58:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vx-548-vertex-pharmaceuticals-peripheral-neuropathic-pain-likelihood-of-approval/ 2024-01-24T19:31:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lx-2006-lexeo-therapeutics-cardiomyopathy-likelihood-of-approval/ 2024-01-04T23:57:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lx-2006-lexeo-therapeutics-friedreich-ataxia-likelihood-of-approval/ 2025-01-21T01:18:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gfh-312-genfleet-therapeutics-shanghai-autoimmune-disorders-likelihood-of-approval/ 2024-09-09T04:58:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sgn-stnv-pfizer-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2024-03-19T00:22:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sgn-stnv-pfizer-peritoneal-cancer-likelihood-of-approval/ 2024-03-19T00:22:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sgn-stnv-pfizer-gastric-cancer-likelihood-of-approval/ 2024-03-19T00:22:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sgn-stnv-pfizer-pancreatic-cancer-likelihood-of-approval/ 2024-03-19T00:22:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sgn-stnv-pfizer-cervical-cancer-likelihood-of-approval/ 2024-03-19T00:22:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sgn-stnv-pfizer-colorectal-cancer-likelihood-of-approval/ 2024-03-19T00:22:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sgn-stnv-pfizer-ovarian-cancer-likelihood-of-approval/ 2024-03-19T00:21:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azd-0901-astrazeneca-adenocarcinoma-of-the-gastroesophageal-junction-likelihood-of-approval/ 2024-09-09T04:58:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pbcar-19b-precision-biosciences-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2024-05-20T04:38:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/wve-006-gsk-alpha-1-antitrypsin-deficiency-a1ad-likelihood-of-approval/ 2024-01-04T23:53:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gene-therapy-to-target-cd19-and-cd22-for-oncology-chongqing-precision-biotech-b-cell-acute-lymphocytic-leukemia-b-cell-acute-lymphoblastic-leukaemia-likelihood-of-approval/ 2024-01-04T23:53:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gene-therapy-to-target-cd19-and-cd22-for-oncology-chongqing-precision-biotech-b-cell-leukemia-likelihood-of-approval/ 2024-01-04T23:53:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ht-6184-halia-therapeutics-myelodysplastic-syndrome-likelihood-of-approval/ 2025-01-21T01:18:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gene-therapy-to-target-cd19-for-oncology-chongqing-precision-biotech-primary-mediastinal-b-cell-lymphoma-likelihood-of-approval/ 2025-01-21T01:17:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gene-therapy-to-target-cd19-for-oncology-chongqing-precision-biotech-follicular-lymphoma-likelihood-of-approval/ 2025-01-21T01:17:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gene-therapy-to-target-cd19-for-oncology-chongqing-precision-biotech-mantle-cell-lymphoma-likelihood-of-approval/ 2025-01-21T01:17:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gene-therapy-to-target-cd19-for-oncology-chongqing-precision-biotech-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2025-01-21T01:17:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gene-therapy-to-target-cd19-for-oncology-chongqing-precision-biotech-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2025-01-21T01:13:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/psilocybin-nova-mentis-biotech-autism-spectrum-disorder-asd-likelihood-of-approval/ 2024-06-19T05:59:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/psilocybin-nova-mentis-biotech-fragile-x-syndrome-likelihood-of-approval/ 2024-01-04T23:50:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cd19-bcma-targeted-car-t-cells-shanghai-yake-biotechnology-acute-lymphocytic-leukemia-all-acute-lymphoblastic-leukemia-likelihood-of-approval/ 2025-01-21T01:13:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gene-therapy-to-target-cd22-for-relapsed-and-refractory-b-cell-non-hodgkin-lymphoma-suzhou-fundamenta-therapeutics-b-cell-non-hodgkin-lymphoma-likelihood-of-approval/ 2024-09-09T04:58:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tas-0612-taiho-oncology-solid-tumor-likelihood-of-approval/ 2025-01-21T01:12:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/campetec-immuron-campylobacter-infections-likelihood-of-approval/ 2025-01-21T01:12:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/srp-3d-south-rampart-pharma-pain-likelihood-of-approval/ 2024-01-04T23:49:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sl-22p-hebei-senlang-biotechnology-refractory-brain-metastasis-likelihood-of-approval/ 2024-04-20T01:14:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sl-22p-hebei-senlang-biotechnology-solid-tumor-likelihood-of-approval/ 2024-04-20T01:14:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sl-22p-hebei-senlang-biotechnology-liver-cancer-likelihood-of-approval/ 2024-04-20T01:14:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/prt-2527-prelude-therapeutics-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2025-01-21T01:12:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/prt-2527-prelude-therapeutics-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-21T01:12:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/prt-2527-prelude-therapeutics-solid-tumor-likelihood-of-approval/ 2025-01-21T01:12:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/prt-2527-prelude-therapeutics-acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-likelihood-of-approval/ 2025-01-21T01:12:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/stem-cell-therapy-for-lung-transplant-rejection-isopogen-lung-transplant-rejection-likelihood-of-approval/ 2024-01-04T23:46:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kesimpta-novartis-multiple-sclerosis-likelihood-of-approval/ 2024-09-09T04:57:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/amlodipine-indapamide-telmisartan-george-medicines-hypertension-likelihood-of-approval/ 2025-01-21T01:12:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gene-therapy-to-target-cd19-and-cd22-for-refractory-and-relapsed-b-cell-acute-lymphoblastic-leukemia-china-immunotech-beijing-biotechnology-b-cell-acute-lymphocytic-leukemia-b-cell-acute-lymphoblastic/ 2024-01-04T23:46:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cb-010-caribou-biosciences-follicular-lymphoma-likelihood-of-approval/ 2024-01-04T23:45:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cb-010-caribou-biosciences-mantle-cell-lymphoma-likelihood-of-approval/ 2024-01-04T23:45:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sp-624-sirtsei-pharmaceuticals-major-depressive-disorder-likelihood-of-approval/ 2024-01-04T23:45:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/agmb-447-agomab-therapeutics-idiopathic-pulmonary-fibrosis-likelihood-of-approval/ 2024-01-04T23:44:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/acetaminophen-nefopam-hydrochloride-aptys-pharmaceuticals-somatic-pain-likelihood-of-approval/ 2024-01-04T23:44:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bi-1910-bioinvent-international-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-04-20T01:14:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bi-1910-bioinvent-international-hepatocellular-carcinoma-likelihood-of-approval/ 2024-04-20T01:14:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sgnpdl-1v-pfizer-ovarian-cancer-likelihood-of-approval/ 2024-01-04T23:43:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sgnb-6a-pfizer-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2024-01-04T23:42:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sgnb-6a-pfizer-adenocarcinoma-of-the-gastroesophageal-junction-likelihood-of-approval/ 2024-01-04T23:42:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sgnb-6a-pfizer-squamous-cell-carcinoma-likelihood-of-approval/ 2024-01-04T23:42:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sgnb-6a-pfizer-bladder-cancer-likelihood-of-approval/ 2024-01-04T23:41:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sgnb-6a-pfizer-gastric-cancer-likelihood-of-approval/ 2024-01-04T23:41:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sgnb-6a-pfizer-cervical-cancer-likelihood-of-approval/ 2024-01-04T23:41:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sgnb-6a-pfizer-ovarian-cancer-likelihood-of-approval/ 2024-01-04T23:41:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/thiscart19a-suzhou-fundamenta-therapeutics-refractory-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2024-04-20T01:14:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/thiscart19a-suzhou-fundamenta-therapeutics-relapsed-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2024-04-20T01:14:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/daratumumab-hyaluronidase-human-recombinant-johnson-johnson-peripheral-neuropathy-sensory-neuropathy-likelihood-of-approval/ 2025-01-21T01:12:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tac-101-triumvira-immunologics-adenocarcinoma-of-the-gastroesophageal-junction-likelihood-of-approval/ 2024-07-05T17:51:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tac-101-triumvira-immunologics-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2025-01-21T01:11:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tac-101-triumvira-immunologics-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-07-05T17:51:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tac-101-triumvira-immunologics-gallbladder-cancer-likelihood-of-approval/ 2024-04-20T01:13:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tac-101-triumvira-immunologics-solid-tumor-likelihood-of-approval/ 2024-07-05T17:51:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tac-101-triumvira-immunologics-gastric-cancer-likelihood-of-approval/ 2024-07-05T17:51:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tac-101-triumvira-immunologics-colorectal-cancer-likelihood-of-approval/ 2024-07-05T17:51:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tac-101-triumvira-immunologics-ovarian-cancer-likelihood-of-approval/ 2024-07-05T17:51:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xtx-101-xilio-therapeutics-merkel-cell-carcinoma-likelihood-of-approval/ 2024-07-05T17:51:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xtx-101-xilio-therapeutics-leiomyosarcoma-likelihood-of-approval/ 2024-07-05T17:51:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xtx-101-xilio-therapeutics-esophageal-cancer-likelihood-of-approval/ 2024-07-05T17:51:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xtx-101-xilio-therapeutics-fallopian-tube-cancer-likelihood-of-approval/ 2024-07-05T17:51:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xtx-101-xilio-therapeutics-uterine-cancer-likelihood-of-approval/ 2024-07-05T17:51:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xtx-101-xilio-therapeutics-gastric-cancer-likelihood-of-approval/ 2024-07-05T17:50:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xtx-101-xilio-therapeutics-cervical-cancer-likelihood-of-approval/ 2024-07-05T17:50:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xtx-101-xilio-therapeutics-prostate-cancer-likelihood-of-approval/ 2024-07-05T17:50:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xtx-101-xilio-therapeutics-breast-cancer-likelihood-of-approval/ 2024-07-05T17:50:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/yt-1920-china-immunotech-b-cell-acute-lymphocytic-leukemia-b-cell-acute-lymphoblastic-leukaemia-likelihood-of-approval/ 2024-01-04T20:53:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/yt-1920-china-immunotech-b-cell-leukemia-likelihood-of-approval/ 2024-01-04T20:52:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sgn-tgt-pfizer-skin-cancer-likelihood-of-approval/ 2024-01-04T20:52:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sgn-tgt-pfizer-bladder-cancer-likelihood-of-approval/ 2024-01-04T20:52:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sgn-tgt-pfizer-gastric-cancer-likelihood-of-approval/ 2024-01-04T20:51:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sgn-tgt-pfizer-cervical-cancer-likelihood-of-approval/ 2024-01-04T20:51:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ibudilast-bumetanide-stalicla-autism-spectrum-disorder-asd-likelihood-of-approval/ 2024-06-19T05:59:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mz-301-maze-therapeutics-chronic-kidney-disease-chronic-renal-failure-likelihood-of-approval/ 2024-01-04T20:50:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lp-659-longboard-pharmaceuticals-neuroinflammation-likelihood-of-approval/ 2024-01-04T20:50:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cc-97540-bristol-myers-squibb-primary-mediastinal-b-cell-lymphoma-likelihood-of-approval/ 2024-07-05T17:50:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cc-97540-bristol-myers-squibb-follicular-lymphoma-likelihood-of-approval/ 2024-07-05T17:50:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sea-cd70-pfizer-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2024-01-04T20:49:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sea-cd70-pfizer-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2024-01-04T20:49:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/auto-8-autolus-therapeutics-refractory-multiple-myeloma-likelihood-of-approval/ 2024-02-22T01:10:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/auto-8-autolus-therapeutics-relapsed-multiple-myeloma-likelihood-of-approval/ 2024-02-22T01:10:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brl-201-brl-medicine-b-cell-acute-lymphocytic-leukemia-b-cell-acute-lymphoblastic-leukaemia-likelihood-of-approval/ 2024-09-09T04:57:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brl-201-brl-medicine-primary-mediastinal-b-cell-lymphoma-likelihood-of-approval/ 2024-09-09T04:57:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brl-201-brl-medicine-follicular-lymphoma-likelihood-of-approval/ 2024-09-09T04:57:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brl-201-brl-medicine-mantle-cell-lymphoma-likelihood-of-approval/ 2024-09-09T04:57:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brl-201-brl-medicine-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2024-09-09T04:57:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/chm-1101-chimeric-therapeutics-recurrent-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-06-19T05:58:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jk-07-salubris-biotherapeutics-diastolic-heart-failure-hfpef-likelihood-of-approval/ 2025-01-21T01:11:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jk-07-salubris-biotherapeutics-systolic-heart-failure-likelihood-of-approval/ 2025-01-21T01:11:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bbt-176-bridge-biotherapeutics-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-01-04T20:46:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gene-therapy-to-target-cd19-and-cd22-for-b-cell-acute-lymphoblastic-leukemia-and-lymphoma-shenzhen-bindebio-b-cell-acute-lymphocytic-leukemia-b-cell-acute-lymphoblastic-leukaemia-likelihood-of-approva/ 2024-04-20T01:13:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gene-therapy-to-target-cd19-and-cd22-for-b-cell-acute-lymphoblastic-leukemia-and-lymphoma-shenzhen-bindebio-lymphoma-likelihood-of-approval/ 2024-04-20T01:13:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xon-7-xenothera-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-01-04T20:45:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xon-7-xenothera-metastatic-ovarian-cancer-likelihood-of-approval/ 2024-01-04T20:44:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xon-7-xenothera-metastatic-colorectal-cancer-likelihood-of-approval/ 2024-01-04T20:44:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xon-7-xenothera-adenocarcinoma-of-the-gastroesophageal-junction-likelihood-of-approval/ 2024-01-04T20:44:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xon-7-xenothera-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-01-04T20:43:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xon-7-xenothera-sarcomas-likelihood-of-approval/ 2024-01-04T20:43:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xon-7-xenothera-metastatic-pancreatic-cancer-likelihood-of-approval/ 2024-01-04T20:43:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gene-therapy-to-target-bcma-and-cd19-for-blood-cancers-and-systemic-lupus-erythematosus-icell-gene-therapeutics-b-cell-acute-lymphocytic-leukemia-b-cell-acute-lymphoblastic-leukaemia-likelihood-of-app/ 2024-05-20T04:36:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gene-therapy-to-target-bcma-and-cd19-for-blood-cancers-and-systemic-lupus-erythematosus-icell-gene-therapeutics-systemic-lupus-erythematosus-likelihood-of-approval/ 2024-05-20T04:36:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mc-225-mc2-therapeutics-uremic-renal-pruritus-likelihood-of-approval/ 2025-01-21T01:11:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bi-905711-boehringer-ingelheim-international-metastatic-colorectal-cancer-likelihood-of-approval/ 2024-07-05T17:50:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bi-905711-boehringer-ingelheim-international-esophageal-cancer-likelihood-of-approval/ 2024-07-05T17:50:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bi-905711-boehringer-ingelheim-international-gastric-cancer-likelihood-of-approval/ 2024-07-05T17:50:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/botulinum-toxin-type-a-microgen-migraine-likelihood-of-approval/ 2024-02-08T04:33:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nkx-019-nkarta-b-cell-acute-lymphocytic-leukemia-b-cell-acute-lymphoblastic-leukaemia-likelihood-of-approval/ 2025-01-21T01:11:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ensomafusp-alfa-f-hoffmann-la-roche-mantle-cell-lymphoma-likelihood-of-approval/ 2025-01-21T01:11:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adi-001-adicet-bio-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2024-02-08T04:33:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adi-001-adicet-bio-follicular-lymphoma-likelihood-of-approval/ 2024-02-08T04:33:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adi-001-adicet-bio-mantle-cell-lymphoma-likelihood-of-approval/ 2024-02-08T04:33:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/auto-1-22-autolus-therapeutics-burkitt-lymphoma-likelihood-of-approval/ 2025-01-21T01:11:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/auto-1-22-autolus-therapeutics-hodgkin-lymphoma-b-cell-hodgkin-lymphoma-likelihood-of-approval/ 2024-01-04T20:38:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/auto-1-22-autolus-therapeutics-chronic-myelocytic-leukemia-cml-chronic-myeloid-leukemia-likelihood-of-approval/ 2024-01-04T20:38:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/auto-1-22-autolus-therapeutics-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2024-01-04T20:37:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/auto-1-22-autolus-therapeutics-acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-likelihood-of-approval/ 2024-01-04T20:37:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/auto-1-22-autolus-therapeutics-acute-lymphocytic-leukemia-all-acute-lymphoblastic-leukemia-likelihood-of-approval/ 2025-01-21T01:11:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ags-v-plus-imutex-zika-virus-infections-likelihood-of-approval/ 2024-09-09T04:57:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ags-v-plus-imutex-west-nile-encephalitis-west-nile-fever-likelihood-of-approval/ 2024-09-09T04:57:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gene-therapy-to-target-cd19-for-leukemia-or-lymphoma-xi-an-yufan-biotechnology-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2024-06-19T05:58:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gene-therapy-to-target-cd19-for-leukemia-or-lymphoma-xi-an-yufan-biotechnology-hairy-cell-leukemia-likelihood-of-approval/ 2024-06-19T05:58:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gene-therapy-to-target-cd19-for-leukemia-or-lymphoma-xi-an-yufan-biotechnology-waldenstrom-macroglobulinemia-lymphoplasmacytic-lymphoma-likelihood-of-approval/ 2024-06-19T05:58:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gene-therapy-to-target-cd19-for-leukemia-or-lymphoma-xi-an-yufan-biotechnology-follicular-lymphoma-likelihood-of-approval/ 2024-06-19T05:58:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gene-therapy-to-target-cd19-for-leukemia-or-lymphoma-xi-an-yufan-biotechnology-burkitt-lymphoma-likelihood-of-approval/ 2024-06-19T05:58:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gene-therapy-to-target-cd19-for-leukemia-or-lymphoma-xi-an-yufan-biotechnology-mantle-cell-lymphoma-likelihood-of-approval/ 2024-06-19T05:58:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gene-therapy-to-target-cd19-for-leukemia-or-lymphoma-xi-an-yufan-biotechnology-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2024-06-19T05:58:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gene-therapy-to-target-cd19-for-leukemia-or-lymphoma-xi-an-yufan-biotechnology-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2024-06-19T05:58:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gene-therapy-to-target-cd19-for-leukemia-or-lymphoma-xi-an-yufan-biotechnology-acute-lymphocytic-leukemia-all-acute-lymphoblastic-leukemia-likelihood-of-approval/ 2024-06-19T05:57:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/agen-1777-bristol-myers-squibb-colon-cancer-likelihood-of-approval/ 2025-01-21T01:11:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brexucabtagene-autoleucel-gilead-sciences-hairy-cell-leukemia-likelihood-of-approval/ 2024-05-20T04:13:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brexucabtagene-autoleucel-gilead-sciences-waldenstrom-macroglobulinemia-lymphoplasmacytic-lymphoma-likelihood-of-approval/ 2024-05-20T04:13:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brexucabtagene-autoleucel-gilead-sciences-burkitt-lymphoma-likelihood-of-approval/ 2025-01-21T01:11:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brexucabtagene-autoleucel-gilead-sciences-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2025-01-21T01:11:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ava-001-avalon-globocare-b-cell-acute-lymphocytic-leukemia-b-cell-acute-lymphoblastic-leukaemia-likelihood-of-approval/ 2024-09-09T04:57:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ava-001-avalon-globocare-non-hodgkin-lymphoma-likelihood-of-approval/ 2024-09-09T04:57:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rmc-6291-revolution-medicines-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-04-20T01:13:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rmc-6291-revolution-medicines-solid-tumor-likelihood-of-approval/ 2024-04-20T01:13:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azd-0780-astrazeneca-dyslipidemia-likelihood-of-approval/ 2024-02-22T01:09:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/allo-501a-allogene-therapeutics-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2024-01-04T20:30:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/allo-501a-allogene-therapeutics-primary-mediastinal-b-cell-lymphoma-likelihood-of-approval/ 2024-01-04T20:30:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anitocabtagene-autoleucel-arcellx-refractory-multiple-myeloma-likelihood-of-approval/ 2025-01-21T01:11:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anitocabtagene-autoleucel-arcellx-relapsed-multiple-myeloma-likelihood-of-approval/ 2025-01-21T01:11:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ad-209-addpharma-idiopathic-essential-hypertension-likelihood-of-approval/ 2024-01-04T20:29:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/yct-529-yourchoice-therapeutics-male-contraception-likelihood-of-approval/ 2025-01-21T01:11:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rapcabtagene-autoleucel-novartis-systemic-lupus-erythematosus-likelihood-of-approval/ 2024-05-20T04:13:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cd19-star-t-cells-china-immunotech-b-cell-non-hodgkin-lymphoma-likelihood-of-approval/ 2024-01-04T20:28:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cd19-star-t-cells-china-immunotech-acute-lymphocytic-leukemia-all-acute-lymphoblastic-leukemia-likelihood-of-approval/ 2024-05-20T04:13:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/yt-19-china-immunotech-b-cell-acute-lymphocytic-leukemia-b-cell-acute-lymphoblastic-leukaemia-likelihood-of-approval/ 2024-01-04T20:28:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ect-001-excellthera-myelodysplastic-syndrome-likelihood-of-approval/ 2024-05-20T04:13:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lixudebart-alentis-therapeutics-kidney-fibrosis-likelihood-of-approval/ 2024-07-05T17:50:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lixudebart-alentis-therapeutics-anti-neutrophil-cytoplasmic-antibody-associated-vasculitis-anca-vasculitis-likelihood-of-approval/ 2024-07-05T17:50:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lesabelimab-dragonboat-biopharmaceutical-shanghai-muscle-invasive-bladder-cancer-mibc-likelihood-of-approval/ 2025-01-21T01:10:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lesabelimab-dragonboat-biopharmaceutical-shanghai-penile-cancer-likelihood-of-approval/ 2025-01-21T01:10:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lesabelimab-dragonboat-biopharmaceutical-shanghai-renal-cell-carcinoma-likelihood-of-approval/ 2025-01-21T01:10:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/acd-856-alzecure-pharma-depression-likelihood-of-approval/ 2025-01-21T01:10:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/orin-1001-shanghai-fosun-pharmaceutical-group-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-04-20T01:12:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/orin-1001-shanghai-fosun-pharmaceutical-group-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2024-05-20T04:13:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/orin-1001-shanghai-fosun-pharmaceutical-group-solid-tumor-likelihood-of-approval/ 2024-05-20T04:13:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/orin-1001-shanghai-fosun-pharmaceutical-group-metastatic-breast-cancer-likelihood-of-approval/ 2024-04-20T01:12:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zeluvalimab-amgen-esophageal-squamous-cell-carcinoma-escc-likelihood-of-approval/ 2024-07-05T17:50:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zeluvalimab-amgen-merkel-cell-carcinoma-likelihood-of-approval/ 2024-07-05T17:50:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zeluvalimab-amgen-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2024-07-05T17:50:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zeluvalimab-amgen-metastatic-transitional-urothelial-tract-cancer-likelihood-of-approval/ 2024-07-05T17:50:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zeluvalimab-amgen-metastatic-renal-cell-carcinoma-likelihood-of-approval/ 2024-07-05T17:50:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zeluvalimab-amgen-thymic-carcinoma-likelihood-of-approval/ 2024-07-05T17:49:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zeluvalimab-amgen-adenocarcinoma-of-the-gastroesophageal-junction-likelihood-of-approval/ 2024-07-05T17:49:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zeluvalimab-amgen-skin-cancer-likelihood-of-approval/ 2024-07-05T17:49:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zeluvalimab-amgen-nasopharyngeal-cancer-likelihood-of-approval/ 2024-07-05T17:49:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zeluvalimab-amgen-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-07-05T17:49:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zeluvalimab-amgen-metastatic-melanoma-likelihood-of-approval/ 2024-07-05T17:49:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zeluvalimab-amgen-metastatic-hepatocellular-carcinoma-hcc-likelihood-of-approval/ 2024-07-05T17:49:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zeluvalimab-amgen-gastric-cancer-likelihood-of-approval/ 2024-07-05T17:49:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zeluvalimab-amgen-cervical-cancer-likelihood-of-approval/ 2024-07-05T17:49:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cd19-22-car-t-hebei-senlang-biotechnology-b-cell-acute-lymphocytic-leukemia-b-cell-acute-lymphoblastic-leukaemia-likelihood-of-approval/ 2024-06-19T05:57:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cd19-22-car-t-hebei-senlang-biotechnology-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2024-01-04T20:19:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cd19-22-car-t-hebei-senlang-biotechnology-primary-mediastinal-b-cell-lymphoma-likelihood-of-approval/ 2024-06-19T05:57:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cd19-22-car-t-hebei-senlang-biotechnology-refractory-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2024-01-04T20:19:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cd19-22-car-t-hebei-senlang-biotechnology-relapsed-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2024-01-04T20:18:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cd19-22-car-t-hebei-senlang-biotechnology-follicular-lymphoma-likelihood-of-approval/ 2024-06-19T05:57:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cd19-22-car-t-hebei-senlang-biotechnology-burkitt-lymphoma-likelihood-of-approval/ 2024-01-04T20:18:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cd19-22-car-t-hebei-senlang-biotechnology-mantle-cell-lymphoma-likelihood-of-approval/ 2024-01-04T20:17:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cd19-22-car-t-hebei-senlang-biotechnology-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2024-06-19T05:57:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gene-therapy-to-target-cd22-for-acute-lymphocytic-leukemia-and-non-hodgkin-lymphoma-hebei-senlang-biotechnology-b-cell-acute-lymphocytic-leukemia-b-cell-acute-lymphoblastic-leukaemia-likelihood-of-app/ 2024-01-04T20:17:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gene-therapy-to-target-ms4a1-for-chronic-lymphocytic-leukemia-refractory-and-relapsed-diffuse-large-b-cell-lymphoma-abelzeta-non-hodgkin-lymphoma-likelihood-of-approval/ 2024-09-09T04:57:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/k-161-kowa-keratoconjunctivitis-sicca-dry-eye-likelihood-of-approval/ 2024-01-04T20:16:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pipe-791-contineum-therapeutics-neuroinflammation-likelihood-of-approval/ 2025-01-21T01:10:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pipe-791-contineum-therapeutics-primary-progressive-multiple-sclerosis-ppms-likelihood-of-approval/ 2025-01-21T01:10:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pipe-791-contineum-therapeutics-secondary-progressive-multiple-sclerosis-spms-likelihood-of-approval/ 2025-01-21T01:10:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pipe-791-contineum-therapeutics-idiopathic-pulmonary-fibrosis-likelihood-of-approval/ 2025-01-21T01:10:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ersm-5404-hibercell-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-04-20T01:12:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bxu-001-baylx-idiopathic-pulmonary-fibrosis-likelihood-of-approval/ 2025-01-21T01:10:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gc-022-gracell-biotechnologies-b-cell-acute-lymphocytic-leukemia-b-cell-acute-lymphoblastic-leukaemia-likelihood-of-approval/ 2024-01-04T20:14:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/uwc-19-uwell-biopharma-acute-lymphocytic-leukemia-all-acute-lymphoblastic-leukemia-likelihood-of-approval/ 2024-09-09T04:57:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jwtcr-001-2seventy-bio-solid-tumor-likelihood-of-approval/ 2024-04-20T01:12:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dazostinag-takeda-pharmaceutical-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2024-05-20T04:11:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dazostinag-takeda-pharmaceutical-solid-tumor-likelihood-of-approval/ 2024-05-20T04:11:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dazostinag-takeda-pharmaceutical-colorectal-cancer-likelihood-of-approval/ 2024-05-20T04:11:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eras-601-erasca-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-01-04T20:12:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/paltimatrectinib-pyramid-biosciences-malignant-glioma-likelihood-of-approval/ 2024-04-20T01:12:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/paltimatrectinib-pyramid-biosciences-solid-tumor-likelihood-of-approval/ 2024-04-20T01:12:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/uliledlimab-i-mab-ovarian-cancer-likelihood-of-approval/ 2025-01-21T01:10:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adapt-001-epicentrx-leiomyosarcoma-likelihood-of-approval/ 2024-09-09T04:57:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adapt-001-epicentrx-chordoma-likelihood-of-approval/ 2024-09-09T04:56:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adapt-001-epicentrx-chondrosarcoma-likelihood-of-approval/ 2024-09-09T04:56:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/acasunlimab-biontech-endometrial-cancer-likelihood-of-approval/ 2024-01-04T20:10:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/linperlisib-shanghai-yingli-pharmaceutical-peripheral-t-cell-lymphomas-ptcl-likelihood-of-approval/ 2025-01-21T01:10:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/linperlisib-shanghai-yingli-pharmaceutical-natural-killer-cell-lymphomas-likelihood-of-approval/ 2025-01-21T01:10:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pegozafermin-89bio-fibrosis-likelihood-of-approval/ 2025-01-21T01:10:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pegozafermin-89bio-liver-cirrhosis-likelihood-of-approval/ 2025-01-21T01:10:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gene-therapy-to-target-cd19-for-acute-lymphoblastic-leukemia-tianjin-mycure-medical-technology-b-cell-acute-lymphocytic-leukemia-b-cell-acute-lymphoblastic-leukaemia-likelihood-of-approval/ 2024-01-04T20:09:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zilovertamab-vedotin-merck-refractory-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2025-01-21T01:10:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zilovertamab-vedotin-merck-relapsed-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2025-01-21T01:09:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zilovertamab-vedotin-merck-follicular-lymphoma-likelihood-of-approval/ 2025-01-21T01:09:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zilovertamab-vedotin-merck-mantle-cell-lymphoma-likelihood-of-approval/ 2025-01-21T01:09:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aiv-001-aiviva-biopharma-basal-cell-carcinoma-basal-cell-epithelioma-likelihood-of-approval/ 2024-01-04T20:07:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/allo-501-allogene-therapeutics-non-hodgkin-lymphoma-likelihood-of-approval/ 2024-09-09T04:56:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jjo-686-novartis-acute-lymphocytic-leukemia-all-acute-lymphoblastic-leukemia-likelihood-of-approval/ 2025-01-21T01:09:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nizubaglustat-azafaros-gm1-gangliosidosis-beta-galactosidase-1-deficiency-likelihood-of-approval/ 2024-01-04T20:06:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nizubaglustat-azafaros-niemann-pick-disease-type-c-likelihood-of-approval/ 2024-07-05T17:48:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nizubaglustat-azafaros-sandhoff-disease-jatzkewitz-pilz-syndrome-likelihood-of-approval/ 2024-02-08T04:32:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nizubaglustat-azafaros-tay-sachs-disease-likelihood-of-approval/ 2024-02-08T04:32:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/luaf-28996-h-lundbeck-parkinson-s-disease-likelihood-of-approval/ 2024-01-04T20:05:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/botensilimab-agenus-solid-tumor-likelihood-of-approval/ 2025-01-21T01:09:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mrg-004a-shanghai-miracogen-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-06-19T05:57:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mrg-004a-shanghai-miracogen-pancreatic-cancer-likelihood-of-approval/ 2024-06-19T05:57:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/volrustomig-astrazeneca-squamous-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-21T01:09:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/volrustomig-astrazeneca-malignant-pleural-mesothelioma-likelihood-of-approval/ 2025-01-21T01:09:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cd19-cd22-car-t-shanghai-unicar-therapy-bio-medicine-technology-acute-lymphocytic-leukemia-all-acute-lymphoblastic-leukemia-likelihood-of-approval/ 2025-01-21T01:09:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sgnbb-228-pfizer-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-01-04T20:02:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sgnbb-228-pfizer-metastatic-melanoma-likelihood-of-approval/ 2024-01-04T20:02:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ninsipapogene-sibarnarepvec-hookipa-pharma-squamous-cell-carcinoma-likelihood-of-approval/ 2024-01-04T20:02:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ide-161-ideaya-biosciences-gastric-cancer-likelihood-of-approval/ 2025-01-21T01:09:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ide-161-ideaya-biosciences-prostate-cancer-likelihood-of-approval/ 2025-01-21T01:09:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/psb-202-qilu-puget-sound-biotherapeutics-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2024-06-19T05:56:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/psb-202-qilu-puget-sound-biotherapeutics-waldenstrom-macroglobulinemia-lymphoplasmacytic-lymphoma-likelihood-of-approval/ 2024-06-19T05:56:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/psb-202-qilu-puget-sound-biotherapeutics-follicular-lymphoma-likelihood-of-approval/ 2024-06-19T05:56:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/psb-202-qilu-puget-sound-biotherapeutics-mantle-cell-lymphoma-likelihood-of-approval/ 2024-06-19T05:56:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/psb-202-qilu-puget-sound-biotherapeutics-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2024-06-19T05:56:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mil-62-beijing-mabworks-biotech-splenic-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2024-01-04T19:59:55+00:00 daily 0.2